


Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

Graphical Abstract



Authors

Adrienne M. Luoma, Shengbao Suo, Hannah L. Williams, ..., Michael Dougan, Guo-Cheng Yuan, Kai W. Wucherpfennig

Correspondence

mldougan@partners.org (M.D.), kai_wucherpfennig@dfci.harvard.edu (K.W.W.)

In Brief

Single-cell analyses of immune checkpoint blockade-associated colitis patient samples reveal enrichment of regulatory T cells in colitic lesions and nominate inflammatory pathways for potential therapeutic intervention.

Highlights

- Mechanisms of inflammatory adverse events induced by checkpoint blockade
- Colitis-associated differentiation of CD8 Trm cells to cytotoxic effector cells
- Persistence and expansion of CTLA-4⁺ Treg cells
- Inflammatory pathways provide opportunities for therapeutic intervention



Article

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

Adrienne M. Luoma,^{1,2,13} Shengbao Suo,^{3,13} Hannah L. Williams,⁴ Tatyana Sharova,^{5,6} Keri Sullivan,⁷ Michael Manos,^{4,8} Peter Bowling,^{4,8} F. Stephen Hodi,^{4,8} Osama Rahma,^{4,9} Ryan J. Sullivan,¹⁰ Genevieve M. Boland,^{5,6} Jonathan A. Nowak,¹¹ Stephanie K. Dougan,^{1,2} Michael Dougan,^{7,14,*} Guo-Cheng Yuan,^{3,14} and Kai W. Wucherpfennig^{1,2,12,14,15,*}

¹Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

²Department of Immunology, Harvard Medical School, Boston, MA 02115, USA

³Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA

⁴Department of Medical Oncology, Dana-Farber Cancer Institute Boston, MA 02215, USA

⁵Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA

⁶Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA

⁷Division of Gastroenterology and Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA

⁸Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

⁹Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, MA, USA

¹⁰Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

¹¹Department of Pathology, Brigham & Women's Hospital, Boston, MA 02115, USA

¹²Department of Neurology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA 02115, USA

¹³These authors contributed equally

¹⁴Senior Author

¹⁵Lead Contact

*Correspondence: mldougan@partners.org (M.D.), kai_wucherpfennig@dfci.harvard.edu (K.W.W.)

<https://doi.org/10.1016/j.cell.2020.06.001>

SUMMARY

Checkpoint blockade with antibodies specific for the PD-1 and CTLA-4 inhibitory receptors can induce durable responses in a wide range of human cancers. However, the immunological mechanisms responsible for severe inflammatory side effects remain poorly understood. Here we report a comprehensive single-cell analysis of immune cell populations in colitis, a common and severe side effect of checkpoint blockade. We observed a striking accumulation of CD8 T cells with highly cytotoxic and proliferative states and no evidence of regulatory T cell depletion. T cell receptor (TCR) sequence analysis demonstrated that a substantial fraction of colitis-associated CD8 T cells originated from tissue-resident populations, explaining the frequently early onset of colitis symptoms following treatment initiation. Our analysis also identified cytokines, chemokines, and surface receptors that could serve as therapeutic targets for colitis and potentially other inflammatory side effects of checkpoint blockade.

INTRODUCTION

Monoclonal antibodies targeting the CTLA-4 or PD-1/PD-L1 pathways can induce durable responses in a wide range of human malignancies but can also induce inflammatory toxicities, collectively referred to as immune-related adverse events (irAEs). These irAEs can affect any organ system and remain a major limitation of checkpoint inhibition (Larkin et al., 2015; Postow et al., 2015, 2018). Nearly 60% of patients treated with a combination of PD-1 and CTLA-4 antibodies develop severe treatment-limiting toxicities (Dougan, 2017; Dougan and Pietropaolo, 2020). The cellular and molecular mechanisms of these immune-related toxicities are not well understood, precluding their optimal clinical management. The most common toxicities occur at barrier sites, including the gastrointestinal (GI) mucosa,

liver, skin, and lungs (Dougan and Pietropaolo, 2020). Checkpoint inhibitor-induced colitis (+CPI colitis) is among the most frequent severe irAEs and is an important cause of treatment discontinuation, particularly in patients receiving a CTLA-4-blocking monoclonal antibody (mAb; ipilimumab) alone or in combination with a PD-1-blocking mAb (nivolumab).

CTLA-4 appears to play a more central role than PD-1 or PD-L1 in gut homeostasis (Joosse et al., 2019; Kuehn et al., 2014; Zeissig et al., 2015). Mild colitis is common in patients receiving ipilimumab, with diarrhea affecting nearly half of the patients on high-dose or combination therapy (Hodi et al., 2010). Severe colon inflammation is less frequent but still occurs in 10%–20% of patients and can be life-threatening (Dougan, 2017; Postow et al., 2018). +CPI colitis is frequently characterized by continuous inflammation from the anus to the cecum, and






Figure 1. Global Analysis of Immune Cell Populations in CPI Colitis

(A) Workflow showing biopsy collection sites and processing of single-cell suspensions for scRNA-seq and flow cytometry. Biopsies were obtained from the following colon segments: rectum (R), sigmoidal (S), and descending (D).

(B) Summary of patient cohorts for scRNA-seq analysis. See [Tables S1–S4](#) and [S5](#) for detailed information.

(C) Identification of colon CD45⁺ immune cell clusters across all samples (n = 5–6 subjects per cohort).

(D) Violin plots showing expression of canonical marker genes across clusters; the y axis represents the normalized gene expression value. See [Table S6](#) for all marker genes.

(legend continued on next page)

histopathological analysis identified a high proportion of lymphocytes and increased numbers of apoptotic epithelial cells (Coutzac et al., 2017; Grover and Srivastava, 2019; Zhang et al., 2020). Although mucosal inflammation induced by CPIs most frequently involves the colon, approximately a quarter of patients with colitis also have inflammation in the small intestine (enteritis) (Downey et al., 2007; Hughes et al., 2019; Zhang et al., 2020). As with most other severe irAEs, current management of CPI colitis includes high-dose, systemic corticosteroids and CPI discontinuation (Postow et al., 2018). Preliminary clinical data indicate that tumor necrosis factor alpha (TNF α) blockade can be efficacious for treatment of +CPI colitis resistant to corticosteroids (Badran et al., 2019). The influence of systemic corticosteroids on anti-tumor responses is presently unknown; corticosteroids induce apoptosis of proliferating T cells, and retrospective data suggest that high-dose corticosteroids may diminish optimal therapeutic responses (Arbour et al., 2018; Faje et al., 2018). Development of alternative treatment approaches targeting inflammatory pathways specific to +CPI colitis without impairing anti-tumor immunity is therefore of crucial importance.

The immunological mechanisms of irAEs have been difficult to study because colitis and other irAEs are not observed in murine tumor models treated with checkpoint inhibitors (Curran et al., 2010). This project was designed to directly study the cellular and molecular mechanisms of colitis as an example of a common and frequently severe irAE. We studied recently diagnosed colitis patients who had not yet received drug treatment for this irAE and used diagnostic tissue biopsies for comprehensive analysis of immune cell populations by single-cell RNA sequencing (scRNA-seq) and multi-spectral flow cytometry. This approach led to discovery of cellular and molecular pathways in +CPI colitis as well as identification of potential therapeutic targets for this important side effect of cancer immunotherapy.

RESULTS

Study Design

We present the first in-depth cellular and molecular analysis of immune cell populations in an irAE induced by checkpoint inhibition therapy with a specific focus on CPI colitis. Immune cell populations were comprehensively studied using two complementary approaches: 5' barcoded scRNA-seq as a discovery tool and multi-spectral flow cytometry for quantification of cell populations and markers at the protein level (Figure 1A). We performed these studies in three patient populations: (1) CPI-treated melanoma patients with histologically confirmed colitis (n = 8, +CPI colitis), (2) healthy adults of similar age undergoing

screening colonoscopies (n = 8, control), and (3) CPI-treated melanoma patients who underwent endoscopic evaluation for suspected +CPI colitis but were found to have a normal colonic mucosa endoscopically and histologically (n = 6, +CPI no colitis) (Figure 1B). This group of drug-exposed patients without colitis was evenly split between patients who had or did not have enteritis (Hughes et al., 2019). Our study design allowed us to distinguish molecular changes induced by drug exposure from the actual disease process. All CPI-treated patients had been recently treated with CTLA-4 and PD-1 antibodies, except for one patient in each group who received anti-CTLA-4 monotherapy (Figure 1B; Tables S1 and S2). Biopsies were obtained soon after development of colitis symptoms (average of 4.5 days, maximum of 13 days) from three major regions of the lower GI tract, predominantly spanning the descending colon through the rectum (Figure 1A). Only a single patient in the cohort received corticosteroids prior to biopsy (Table S3). Tissue specimens were enzymatically digested to liberate cells from the lamina propria (LP) and epithelial layer, which also contains intraepithelial lymphocytes (IELs). We sequentially isolated live CD45⁺ mononuclear cells as well as CD3⁺ T cells by fluorescence-activated cell sorting (FACS) for scRNA-seq using 10X Genomics 5' barcoding technology (Figures 1A and S1A).

Global Analysis of Immune Cell Populations in +CPI Colitis

We prepared scRNA-seq libraries from CD45⁺ immune cells for 16 patients (n = 6 +CPI colitis, n = 5 +CPI no colitis, n = 5 control), which provided high-quality transcriptomes for a total of 51,652 cells (Figures 1B and S1B). Data integration revealed 16 distinct clusters comprising all expected immune cell populations, including T cells, B cells, immunoglobulin A (IgA)⁺ plasma B cells, myeloid cells, mast cells, and innate lymphoid cells (ILCs); neutrophils were excluded by FACS because of their incompatibility with the 10X Genomics platform (Figures 1C, 1D, and S1C). Each cluster contained cells from all patients, indicating the absence of major patient-specific batch effects (Figure 1E and 1F). The most striking changes between +CPI colitis and control groups were observed in the T cell compartment, which was represented by six clusters in this CD45⁺ dataset. In particular, we observed substantial shifts in the structure of T cell populations; in colitis compared with control cases, we identified a striking increase in the fraction of T cells in clusters 15 (CD8⁺ cytotoxic lymphocytes, CTL) and 16 (cycling T cells) (Figures 1E–1G and S1D). T cell populations in both control groups (+CPI no colitis and control) were significantly different from those in colitis patients, indicating that these changes in T cell populations were related to the

(E) Distribution of CD45⁺ immune cells across clusters colored based on patient groups.


(F) Cell cluster frequency shown as a fraction of total cells for each patient, CT, control; NC, no colitis; C colitis.

(G) Quantification of immune cell distribution across clusters and comparison of patient groups. For each cluster, the average fraction of cells from each patient group is shown, after normalization for total input cell numbers per patient (STAR Methods). Average and SEM are shown for each patient group. Statistical analysis compares control and +CPI colitis patient groups. *p < 0.05, **p < 0.01, two-sided Wilcoxon test.

(H) Flow cytometry analysis of CD3⁺ T cells in colon biopsies (percentage of live CD45⁺ cells averaged across colon regions) in all patients (n = 7–10 subjects per group; see Table S5 for details regarding analyzed cases). *p < 0.05, ***p < 0.001, one-way ANOVA test; error bars, SD.

(I) Comparison of T cell frequencies as determined by flow cytometry (percentage of live CD45⁺ cells) versus scRNA-seq (percentage of live CD45⁺ MNC cells) and fit with a linear regression model.

See also Figure S1 and Tables S1–S4.



(legend on next page)

disease state rather than drug exposure (Figures 1E and S1D). Similar changes in T cell clusters were observed in colitis patients exposed to different CPI drugs, including monotherapy with ipilimumab (patient C2), combination therapy with ipilimumab and nivolumab (patient C3), and sequential pembrolizumab and ipilimumab (patient C1) (Figure S1D). Flow cytometry analysis confirmed the +CPI colitis-associated increase in relative CD3⁺ T cell frequency and absolute number (Figures 1H, S1E, and S1F). T cell frequency, quantified by flow cytometry and scRNA-seq, was strongly correlated, serving as cross-validation of these experimental methods (Figure 1I). In addition to these changes in the T cell compartment, we also observed an increase in the frequency of myeloid cells in colitis patients compared with healthy control subjects (Figures 1E and 1G). These results demonstrate that +CPI colitis is associated with major changes in colonic immune cells, including cytotoxic and cycling T cells as well as myeloid-lineage cells.

Colitis-Related Changes in CD8⁺ T Cell Cytotoxicity and Proliferation Programs

We additionally generated scRNA-seq libraries for CD3⁺ T cells from 22 subjects (Figure 1B), which provided transcriptomes for 67,926 cells and corresponding T cell receptor (TCR) sequences (Figures S2A–S2G). We analyzed major T cell lineages by flow cytometry and found that the frequency of CD8⁺ T cells (defined as CD4[−] because of partial CD8 cleavage by tissue digestion enzymes) among total CD3⁺ cells was similar among the three patient groups, indicating that CD4⁺ and CD8⁺ T cells were expanded in colitis patients (Figures S2H–S2J). Non-classical T cell lineages present in the colon, including $\gamma\delta$ T cells and mucosa-associated invariant T (MAIT) cells, did not significantly differ among the three patient groups (Figures S2K and S2L).

Sub-clustering of CD8⁺ T cells revealed eight well-defined sub-populations that were annotated based on published signatures and cell markers (Figures 2A, 2B, S3A, and S3B; Martin et al., 2019; Smillie et al., 2019). The overall organization of the CD8⁺ T cell compartment showed striking differences between +CPI colitis patients and both control groups: clusters 7 (cytotoxic ef-

factors) and 8 (cycling T cells, *MKI67*⁺) were nearly exclusive to +CPI colitis patients (Figures 2C–2E). T cells from colitis patients were also enriched in two smaller clusters (cluster 6, central memory/naive cells; cluster 5, terminal effector cells). In contrast, the fraction of T cells from clusters representing tissue-resident memory T (Trm) cells was reduced in +CPI colitis patients (Figure 2E; Kumar et al., 2017). CD8⁺ T cells from clusters 7 and 8 showed high expression of cytotoxicity genes, including *GZMB* (Figure 2F) and characteristic interferon γ (IFN γ) response genes (*HLA-DRA* and *CD74*) (Figures 2B, S3C, and S3D).

We confirmed the increased frequency of cytotoxic effector CD8⁺ T cells in +CPI colitis patients by flow cytometry for the same patient cohort (Figures 2G–2I). Importantly, a colitis patient who received ipilimumab monotherapy also had a large fraction of granzyme B⁺ CD8⁺ T cells (59.5%), suggesting that the increase in cytotoxic CD8⁺ T cells was not restricted to combination CPI (Figure S3E). The percentage of granzyme B⁺ CD8⁺ T cells was also increased in +CPI-treated patients without colitis compared with healthy control subjects, demonstrating that CPI itself caused elevation of the cytotoxicity program (Figure 2G). Mirroring the scRNA-seq data, cycling (Ki-67⁺) granzyme B⁺ CD8⁺ T cells were increased dramatically in +CPI colitis patients (Figures 2H and 2I), whereas Trm populations were reduced (Figures 2J and 2K).

To determine the localization of cycling cytotoxic T cells, we performed multi-color immunofluorescence analysis of tissue sections in +CPI colitis compared with healthy subjects. Large clusters of cycling (Ki-67⁺) CD8⁺ and CD4⁺ cells were predominantly localized in the LP in +CPI colitis patients treated with CTLA-4 and PD-1 antibodies (Figure 2L); fewer CD8⁺ and CD4⁺ cells were observed in the LP of healthy subjects. These data demonstrate striking colitis-associated changes in colonic CD8⁺ T cells, characterized by a shift from Trm to cytotoxic, cycling effector T cells.

Increase in CD4⁺ Effector and Regulatory T Cells in +CPI Colitis

Sub-clustering of CD4⁺ T cells revealed 10 populations that showed major differences between +CPI colitis and control

Figure 2. Colitis-Related Changes in CD8⁺ T Cell Cytotoxicity and Proliferation Programs

(A) Sub-clustering of CD8 T cells selected from the CD3⁺ dataset for all subjects (n = 6–8 patients per group; STAR Methods).

(B) Violin plots displaying marker genes of CD8 T cell clusters. For each cluster, the gene with the highest-scoring cell type specificity score (STAR Methods) and a highly expressed well-defined subset marker are shown. Bottom: *IFNG* expression across clusters. The y axis represents the normalized gene expression value. See Table S6 for all marker genes.

(C) Distribution of CD8 T cells across clusters among patient groups.

(D) Distribution of CD8 T cells across the eight clusters for each patient, CT, control; NC, no colitis; C, colitis.

(E) Quantification of cell cluster frequency representation among patient groups. Average and SEM are shown for each patient group. *p < 0.05, **p < 0.01, ***p < 0.001, two-sided Wilcoxon test comparing control and +CPI colitis groups.

(F) Expression of *GZMB* across clusters in the three patient groups.

(G) Quantification of granzyme B⁺ CD8 T cells by flow cytometry (percentage of CD4[−] $\alpha\beta$ TCR⁺ non-MAIT (V α 7.2[−] CD161[−]) cells pre-gated on live CD45⁺ CD3⁺ cells) for all patients (n = 7–10 subjects per group) averaged across colon regions. **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA test; error bars, SD.


(H) Quantification of granzyme B⁺ Ki-67⁺ CD8 T cells by flow cytometry gated as in (I). Ki-67 antibody staining was not performed for initial patients (n = 4–10 subjects per group, averaged across colon regions). *p < 0.05, one-way Brown-Forsyth and Welch ANOVA test; error bars, SD.

(I) Representative flow cytometry plots for (G) and (H).

(J and K) Quantification (J) and representative flow plots (K) of CD103⁺ CD69⁺ CD8 Trm cells (n = 6–10 subjects per group). **p < 0.01, one-way ANOVA test; error bars, SD.

(L) Multiplex immunofluorescence images of formalin-fixed paraffin-embedded (FFPE) sections from +CPI colitis (treated with α -CTLA-4 and α -PD-1 mAbs) and control patients in a separate cohort (2 representative cases are shown for each). Sections were stained with the indicated antibodies and counterstained with DAPI. A dashed box represents the 4 \times enlarged area shown in the center panel. White arrows point to cells positive for Ki-67 and CD8.

See also Figure S3.



(legend on next page)

cases; notably, clusters 9 and 10 were nearly exclusively comprised of cells from +CPI colitis patients (Figures 3A–3D, S4A, and S4B). Cells in cluster 9 were Th1 effector cells that highly expressed a number of IFN γ -inducible genes, including *GBP1/5*, *STAT1*, and *CD74* (Figures 3B and S4A–S4D). Cluster 10 was comprised of *MKI67*⁺ cycling conventional and regulatory T (Treg) cells, which we corroborated at the protein level (Figures 3B, 3J, 3K, and S4A). A population of cytotoxic CD4⁺ T cells (cluster 8) was identified based on expression of *GZMA* and *GZMH*. Although this cluster was not enriched in +CPI colitis cases, *GZMA* was a top differentially expressed gene in CD4⁺ T cells from colitis-associated clusters (9 and 10) compared with non-colitis clusters (1–8) (Figure S4C). Similar to CD8⁺ Trm T cell populations, Trm clusters 1 and 3 were reduced as a fraction of CD4⁺ T cells in colitis patients (Figure 3D).

CTLA-4 is highly expressed by FoxP3⁺ Treg cells, and studies using mouse models have indicated that CTLA-4 antibody therapy can induce depletion of Treg cells in tumors (Simpson et al., 2013). Depletion of CTLA-4⁺ Treg cells has therefore been hypothesized to cause the high frequency of irAEs in ipilimumab-treated patients, although evidence in human cases does not support this model (Coutzac et al., 2017; Lord et al., 2010; Sharma et al., 2019). Flow cytometry analysis showed that the percentage of FoxP3⁺ cells within the total CD4⁺ T cell population was significantly elevated in +CPI colitis patients compared with both control groups, consistent with increased Treg cell proliferation (Figures 3E, 3K, and S4F). FoxP3 protein levels were higher in Treg cells from +CPI colitis patients compared with healthy control subjects (Figures 3F and 3G). High FoxP3 levels are characteristic of *bona fide* Treg cells, whereas activated effector T cells transiently express FoxP3 at a lower level (Miyara et al., 2009; Wang et al., 2007). *CTLA4* mRNA and CTLA-4 protein levels were also maintained in CD4⁺ T cells from +CPI colitis patients compared with both control groups (Figures 3H, 3I, and S4A).

Further analysis of cluster 7 identified five sub-clusters; cells in four of these sub-clusters expressed high levels of *FOXP3*, as

expected for Treg cells (clusters 1–4) (Figures 3L–3N and S4G). Cluster 1 Treg cells expressed several genes characteristic of Th1 cells, such as *IL12RB2* (interleukin-12 [IL-12] receptor), *CXCR3*, and *STAT1*, and this population was enriched in +CPI colitis patients (Figures 3O, S4H, and S4I). In response to IFN γ , Treg cells upregulate Th1 programs, which enhance their regulatory function for suppression of IFN γ -producing Th1 effector cells (Koch et al., 2009). The transcriptional program of cluster 1 Treg cells may therefore be related to IFN γ production by effector T cells. These data demonstrate that colitis induced by combination CPI or anti-CTLA-4 monotherapy is not caused by depletion of CTLA-4⁺ Treg cells (Figures 3E–3I and S4E) and that the inflammatory environment alters the gene expression programs of Treg cells.


Shared TCRs between Colitis-Associated and Trm CD8⁺ T Cell Clusters

We next aimed to investigate the origin of T cells in colitis-associated clusters, in particular with respect to a potential relationship to Trm cells. This question is particularly relevant for irAEs affecting epithelial tissues (including skin, lung, and gut) because these environmental interfaces are infiltrated by substantial populations of Trm cells (Masopust and Soerens, 2019; Szabo et al., 2019). T cells undergo clonal expansion following TCR activation, enabling use of TCR sequences (clonotypes) as molecular barcodes for mapping of differentiation trajectories. Most cells from the CD4 and CD8 datasets expressed an $\alpha\beta$ TCR (average of 91.0% of CD8 and 98.9% of CD4 T cells), with the exception of the CD8 cluster 1 (IELs), which contained a substantial population of $\gamma\delta$ T cells (Figures S5A and S5F–S5H). The high fraction of expanded CD8⁺ T cells permitted a robust comparison of TCR clonotype sharing between clusters (Figure S5B).

We investigated whether TCRs from clonally expanded CD8⁺ T cells could be identified in multiple clusters. For each patient, we determined the number of expanded TCR clonotypes that were shared by two or more clusters and then aggregated these data for each patient group to evaluate disease-associated TCR

Figure 3. Increase in CD4⁺ Effector Cells and Treg Cells in CPI Colitis

- (A) CD4 T cells were selected from the CD3⁺ dataset for all subjects (n = 6–8 patients per group) and sub-clustered. Trm-A and Trm-R, activated and resting tissue-resident memory T cells, respectively.
- (B) Violin plots displaying marker genes for CD4 T cell clusters (see Figure 2B for details). See Table S6 for all marker genes.
- (C) Distribution of CD4 T cells across clusters among patient groups.
- (D) Quantification of cell cluster frequency representation among patient groups. Average and SEM are shown for each patient group. *p < 0.05, **p < 0.01, ***p < 0.001, two-sided Wilcoxon test comparing control and +CPI colitis groups.
- (E) Quantification of Treg cells (percentage of Foxp3⁺CD4⁺ cells pre-gated on live CD45⁺ CD3⁺ $\gamma\delta$ TCR[−] cells) for all patients (n = 7–10 subjects per group) averaged across colon regions. **p < 0.01, one-way ANOVA test.
- (F) Geometric mean fluorescence intensity (gMFI) of Foxp3 staining gated on CD4⁺ Foxp3⁺ cells (n = 6–10 subjects per group) averaged across colon regions. **p < 0.01, one-way ANOVA test.
- (G) Representative flow plots for (E) and (F).
- (H) Quantification of CTLA-4 expression by FoxP3⁺ CD4⁺ Treg cells (n = 6–10 subjects per group). N.S., one-way ANOVA test.
- (I) Representative plots for (H), showing CTLA-4 levels of FoxP3⁺ Treg cells and Foxp3[−] Th CD4⁺ cells compared with the fluorescence-minus-one (FMO) gating control.
- (J and K) Quantification and representative flow cytometry plots of Ki-67⁺ Foxp3[−] CD4 T cells (J) and Foxp3⁺ CD4 T cells (K) (n = 4–10 subjects per group) averaged across colon regions. *p < 0.05, one-way Brown-Forsyth and Welch ANOVA test; error bars, SD.
- (L and M) Sub-clustering of Treg cells from cluster 7 from (A), colored according to patient group (L) and sub-cluster annotation (M).
- (N) Normalized *FOXP3* expression across Treg cell sub-clusters.
- (O) Heatmap showing differentially expressed genes across Treg cell sub-clusters. From the top 10 cluster-defining genes, five with high relevance for Treg cell function are shown. See Table S6 for all marker genes.
- See also Figure S4.



(legend on next page)

clonotype sharing (Figures 4A and S5C). In +CPI colitis patients, 94.2% of expanded TCRs in cluster 8 (cycling cells) were shared with cluster 7 (cytotoxic effector cells), revealing a dynamic connection between these two colitis-associated CD8⁺ T cell states. In colitis patients, a large percentage of clonally expanded TCRs from Trm T cell clusters (1–3) were shared with colitis-associated clusters 7 and 8 (56.62% of expanded TCRs from clusters 1–3 shared with clusters 7 and 8) (Figures 4A–4C).

We also systematically examined sharing of expanded TCR clonotypes across all combinations of clusters (Figures 4C and 4D). Inter-cluster sharing of expanded TCRs was dramatically altered among patient cohorts. In control groups, expanded TCR clonotypes were primarily shared between Trm clusters 1 and 2. In contrast, +CPI colitis patient TCR clonotypes significantly overlapped between clusters 7 and 8 as well as clusters 7 and 2. Single-cell transcriptome data were also used to infer dynamic changes between cell populations by computation of splicing-based RNA velocity (La Manno et al., 2018). This analysis revealed a potential differentiation trajectory from Trm to cytotoxic effector cells (Figure 4E). CD4 T cells exhibited less overall clonal expansion (Figures S5B, S5D, and S5E), consistent with lower proliferation in response to common viral pathogens compared with CD8 T cells (Foulds et al., 2002). These data demonstrate a dynamic connection between colitis-associated CD8 T cell clusters and Trm CD8 T cell clusters in +CPI colitis patients.

Gene Expression Programs of Colitis-Associated T Cell Populations

We next evaluated the expression of inhibitory receptors by colitis-associated CD8⁺ and CD4⁺ T cell populations. *CTLA4* gene expression was significantly upregulated in colitis-associated CD8⁺ and CD4⁺ T cell clusters (Figure 5A–5C, 5E–5G, S6D, and S6E). At the protein level, an increased percentage of CD8⁺ T cells expressed granzyme B and CTLA-4 in +CPI colitis patients compared with control subjects (Figures S6A–S6C). We also observed elevated expression of *PDCD1* (encoding PD-1) in colitis-associated CD8⁺ and CD4⁺ clusters (Figures 5B, 5C, 5F, and 5G). Antibodies specific for TIM-3 and LAG-3 are currently being evaluated as alternative cancer immunotherapies, and expression of the corresponding genes *HAVCR2* and *LAG3* was elevated in colitis-associated CD8⁺ T cells (cluster 7) and,

to a lesser extent, in CD4⁺ T cells (cluster 10) (Huang et al., 2019; Solomon and Garrido-Laguna, 2018).

To define common molecular pathways and potential targets for intervention, we evaluated the most differentially expressed genes in colitis-associated clusters. The cytotoxicity genes *GZMB* and *GZMA* (CD8⁺ T cells) and *GZMA* (CD4⁺ T cells) were the top differentially expressed genes in colitis-associated clusters (Figures 5D, 5H, S3C, and S4C). A number of colitis-associated upregulated genes were characteristic of an IFN γ response, consistent with elevation of *IFNG* mRNA in colitis-associated CD8⁺ and CD4⁺ T cell clusters (Figures 2B, S3D, 3B, and S4D). These include guanylate exchange factors (*GBP5*) as well as genes of the major histocompatibility complex (MHC) class II antigen presentation pathway (*HLA-DR* and *CD74*), which is increased in T cells during activation and in response to IFN γ signaling. We analyzed hallmark gene sets collected from the Molecular Signatures Database (Liberzon et al., 2015) and found that IFN γ response genes (and overlapping IFN α response genes) were highly enriched in colitis-associated CD4⁺ and CD8⁺ T cell clusters (Figure S6F). IFN γ can directly induce apoptosis in colonic epithelial cells and enhance antigen presentation to T cells by MHC class I and class II pathways (Langer et al., 2019; Neurath, 2014).

Inflammatory Gene Expression Signatures in Myeloid Cells

To identify colonic immune cell populations responding to T cell effector programs, we analyzed inflammatory gene expression signatures across all populations in the CD45⁺ dataset (Figure 1C). We found that IFN γ - and TNF α -induced signatures were significantly upregulated in myeloid cells (cluster 5) compared with all other immune cell populations (Figure 6A). The top differentially expressed genes in myeloid cells from +CPI colitis compared with control patients were IFN γ response genes, including *CXCL9* and *CXCL10*, which encode chemokines that recruit CXCR3⁺ effector T cells to sites of inflammation (Figure 6B). Pathway enrichment analysis also showed that gene sets associated with IFN γ response and TNF α signaling were upregulated by myeloid cells in +CPI colitis versus control patients (Figure 6C). Sub-clustering of myeloid cells revealed three macrophage/monocyte clusters (1–3), one dendritic cell cluster (4), and one cluster representing macrophages that may have phagocytosed T cells (5; co-expression

Figure 4. Tracking of Clonal Expansion across CD8 T Cell Clusters

(A) Sharing of expanded TCR clonotypes across clusters. For each patient and cluster, the number of expanded TCR clonotypes from the CD8⁺ dataset was calculated and summed up for the indicated patient groups. Expanded clonotypes shared with a colitis-associated cluster (5–8) are colored red, and those shared with other clusters (1–4) are colored blue.

(B) Visualization of TCR clonotypes identified in Trm and colitis-associated clusters. Top panel: CD8 T cells with expanded clonotypes present in clusters 2 and 7. Bottom panel: CD8 T cells with expanded clonotypes present in clusters 2, 7, and 8. Some clonotypes are also shared with other clusters, but only sharing with the indicated clusters is visualized.

(C) Sharing of expanded TCR clonotypes across all possible combinations of CD8 T cell clusters. Data were aggregated for each of the indicated patient groups. Numbers indicate the number of shared expanded TCR clonotypes for each cluster pair. Bold boxes indicate statistically significant sharing of expanded clonotypes between clusters (adjusted $p < 0.05$, one-sided Fisher's exact test followed by Benjamini-Hochberg correction).

(D) Visualization of data from (C) as a network plot. Nodes represent cell clusters. The size of the nodes represents the log₂-transformed cell numbers from each patient group. The width of connecting lines indicates the number of shared expanded clonotypes between two clusters, and the color gradient of lines reflects the statistical significance of clonotype sharing.

(E) RNA velocity analysis of gene expression in the CD8⁺ dataset. Arrows denote velocity vectors illustrating potential differentiation paths.

See also Figure S5.




Figure 5. Analysis of T Cell Checkpoints and Colitis-Associated Genes

(A) CD8⁺ T cell cluster representation from Figure 2A as a uniform manifold approximation and projection (UMAP) plot (repeated to aid with analysis of gene expression data).

(B) Normalized expression of T cell checkpoint genes among CD8⁺ clusters, shown as violin plots. ***adjusted (Adj.) p = 10E-100-200, ****Adj. p < 10E-200.

(C) Expression of inhibitory receptors by CD8⁺ T cells.

(legend continued on next page)

of macrophage and T cell genes but low doublet score) (Figures 6D–6H). Most macrophages in cluster 1 originated from +CPI colitis patients (Figure 6F) and exhibited elevated expression of IFN γ -inducible genes, including *CXCL9* and *CXCL10* (Figures 6G and 6I). Macrophages in cluster 1 also had an elevated TNF α signaling gene expression signature (Figure 6I). These data demonstrated that IFN γ changes the gene expression program of myeloid cells and induces expression of chemokines that can recruit effector T cells to sites of inflammation.

Potential Therapeutic Targets Arising from T Cell-Myeloid Cell Connectivity

We considered two molecular mechanisms as opportunities for therapeutic intervention in +CPI colitis: recruitment of T cells and production of soluble inflammatory mediators. The chemokine receptor genes *CXCR3* and *CXCR6* were upregulated in T cells from +CPI colitis patients compared with control subjects (Figures 7A–7D and S7A). *CXCR6* was one of the top differentially expressed genes in colitis-associated CD4⁺ T cell populations (Figure 5H), and the ligand encoded by *CXCL16* was expressed by myeloid cells and mast cells. Interestingly, *CXCR6* is overexpressed in a variety of human cancers (including prostate, breast, gastric, lung, and ovarian cancer) and plays an important role in metastasis (Xiao et al., 2015). *CXCR6* inhibition may therefore reduce cancer cell metastasis and also ameliorate inflammation in the colon, although the role of this chemokine receptor in tumor immunity remains to be studied further. Overexpression of the *CXCR3* gene by T cells (Figure 7D) and *CXCL9* and *CXCL10* by myeloid cells (Figures 7C and 6B) in +CPI colitis patients suggests that such T cell-myeloid crosstalk is also important for T cell recruitment.

The integrin $\beta 7$ subunit (*ITGB7* gene) pairs with the αE (*ITGAE*) or $\alpha 4$ (*ITGA4*) subunits to form the $\alpha E\beta 7$ and $\alpha 4\beta 7$ receptors. The $\alpha E\beta 7$ integrin is a hallmark of Trm T cells and enables adherence to E-cadherin-expressing epithelial cells (Ceppek et al., 1994; Szabo et al., 2019). The *ITGAE* chain was highly expressed by CD8⁺ T cells in colitis-associated clusters (7, 8, and 5) and Trm clusters (Figures 7E and S7B). *ITGAE* expression was lower in CD4⁺ T cell clusters, although a substantial fraction of cycling CD4⁺ cells (cluster 10) also expressed this gene. The $\alpha 4\beta 7$ integrin enables recruitment of T cells from the blood into the gut, and the *ITGA4* gene was elevated in CD4⁺ colitis-associated clusters (9 and 10) and Treg cells (cluster 7) as well as in a fraction of CD8⁺ cytotoxic effector cells (cluster 7) (Figures 7E and S7B). Preliminary clinical data indicate that vedolizumab, a $\alpha 4\beta 7$ integrin-specific mAb, has efficacy in +CPI colitis patients who failed to respond to corticosteroids (Abu-Sbeih et al., 2018). A mAb specific for the $\beta 7$ chain, which inhibits the function of $\alpha E\beta 7$ and $\alpha 4\beta 7$ integrin, could also be a therapeutic opportunity for +CPI colitis.

Finally, we investigated the expression of cytokines and their receptors in T cell and myeloid cell populations. A number of cytokine-receptor pairs were upregulated in +CPI colitis patients

(Figures 7F, 7G, and S7C). Myeloid cells from +CPI colitis compared with healthy control subjects overexpressed several cytokine genes related to intestinal homeostasis, including *TNF*, *IL1B*, and *OSM* (Maloy and Powrie, 2011; West et al., 2017); some of these transcripts were also elevated in myeloid cells from +CPI no-colitis patients compared with healthy control subjects. Preliminary clinical data indicate that TNF α blockade can be efficacious for treatment of +CPI colitis resistant to corticosteroids (Badran et al., 2019), and an increased TNF α -induced gene expression signature was observed in myeloid cells from +CPI colitis compared with control subjects (Figure 6C). IL-1 release is induced by activation of the NLRP3 inflammasome, and we found that a signature representing regulation of inflammasome expression was higher in myeloid cells from +CPI colitis compared with control subjects (Figures 7H, 7I, S7D, and S7E). We also examined a signature comprised of genes encoding the NLRP3 inflammasome core pathway, which was expressed in all myeloid cells but elevated in clusters 1 and 2 (Figure S7F). Single-cell analysis of *IL1B* and NLRP3 inflammasome core pathway genes showed highly significant co-expression (Figure S7G). In a recent clinical trial that evaluated the IL-1 β blocking antibody canakinumab in patients with atherosclerosis, the incidence of newly diagnosed lung cancer and lung cancer mortality were significantly reduced in the canakinumab treatment arm compared with the placebo group (Ridker et al., 2017), and this mAb could also represent an opportunity for treatment of +CPI colitis.

DISCUSSION

This comprehensive single-cell analysis of +CPI colitis identified major changes in immune cell composition and effector programs underlying this common and severe irAE. TCR $\alpha\beta$ analysis demonstrated a connectivity between CD8 Trm cells and emergence of cytotoxic effector cells in +CPI colitis patients. Colitis may be a relatively common and early irAE because a large number of such tissue-resident CD8⁺ T cells are already present in the healthy colon. We therefore hypothesize that activation of tissue-resident CD8 T cells plays an important role in colitis and that activation of such T cells induces subsequent recruitment of additional CD8 and CD4 T cell populations from the blood.

The pronounced activation and proliferation of cytotoxic effector CD8⁺ T cells in +CPI colitis may in part explain the response to systemic corticosteroid therapy because corticosteroids induce apoptosis of activated T cells (Herold et al., 2006). Many other irAEs associated with CPIs also respond to corticosteroids, consistent with the hypothesis that highly activated T cells may also be present in other tissues affected by irAEs. The large fraction of cycling T cells in +CPI colitis may also explain the clinical observation that this irAE often occurs with rapid onset and escalates over a period of days rather than weeks, as is typical for inflammatory bowel disease (IBD) (Dougan, 2017). In contrast, tumor-infiltrating T cells are far

(D) Ranking of significantly differentially expressed genes in colitis-associated clusters (5–8) compared with other clusters (1–4). The top 10 positive and negative differentially expressed genes are labeled. See Table S7 for all differentially expressed genes.

(E–H) The same analyses as shown in (A)–(D), respectively, but for the CD4⁺ dataset.

See also Figure S6.




Figure 6. Inflammatory Gene Expression Signatures in Myeloid Cells

(A) Hallmark gene set scores for IFN γ response (top) and TNF α signaling via nuclear factor κ B (NF- κ B) (bottom), computed for all clusters in the aggregated CD45⁺ dataset (all patients combined). ***p = 10E-100-200, two-sided Wilcoxon test.

(B) Ranking of significantly differentially expressed genes among myeloid cells in the indicated comparisons of patient groups. The top 10 positively/negatively differentially expressed genes are labeled. See Table S7 for all differentially expressed genes.

(C) Functional enrichment analysis of significant hallmark gene sets comparing myeloid cells from +CPI colitis patients with healthy control patients. NES, normalized enrichment score.


(D and E) Sub-clustering of myeloid cells from cluster 5 (Figure 1C) colored according to patient group (D) and sub-cluster annotation (E).

(F) Quantification of myeloid cell distribution frequency and representation among patient groups. Average and SEM are shown for each patient group. *p < 0.05, **p < 0.01, two-sided Wilcoxon test comparing control and +CPI colitis groups.

(G) Heatmap showing differentially expressed genes across myeloid sub-clusters. Genes of interest from the top 10 cluster-defining genes are shown. See Table S6 for all marker genes.

(H) Cell doublet likelihood was calculated with DoubletFinder, showing no significant differences among clusters.

(I) Hallmark gene set activity scores computed for each myeloid sub-cluster (aggregated cells from all patients). *p = 10E-05-50, ***p = 10E-100-200, two-sided Wilcoxon test.



(legend on next page)

less proliferative following checkpoint blockade because of T cell exhaustion (McLane et al., 2019). This lower proliferative capacity may explain why anti-tumor effects of checkpoint blockade are not fully abrogated by systemic corticosteroid exposure. Nevertheless, some deleterious effects of prolonged high-dose corticosteroids on anti-tumor immunity are likely, underscoring the importance of identifying alternative therapeutic targets.

Recent single-cell analyses of intestinal Crohn's disease and ulcerative colitis (UC) lesions provide an opportunity for comparison with +CPI colitis (Martin et al., 2019; Smillie et al., 2019). Proliferating T cells were increased in UC, Crohn's disease, and +CPI colitis compared with healthy colon tissue; however, their elevation was most pronounced in +CPI colitis. T cell cytokine profiles also showed substantial differences between these forms of colitis; UC was characterized by an increase in IL-17⁺ CD8 T cells, whereas IL-17 expression was unchanged in +CPI colitis. In contrast, T cell IFN γ expression and IFN γ -inducible genes were strongly increased in +CPI colitis compared with control subjects. In UC and Crohn's disease, there was a shift from IgA⁺ to IgG⁺ plasma B cells that was not observed in +CPI colitis, which may be related to differences in underlying mechanisms and disease state. These data suggest that there are important differences in T cell functional states, T cell cytokine expression programs, and B cell-mediated immunity between IBD and +CPI colitis.

Colitis-associated T cell populations expressed high levels of *CXCR6* and *CXCR3* chemokine receptor genes. *CXCL16*, which encodes the ligand for *CXCR6*, was expressed by colonic myeloid cells and mast cells, and its expression is known to be regulated by IFN γ and TNF α . *CXCR6* and *CXCL16* are potential targets for the treatment of colitis, in particular because this chemokine-receptor pair also contributes to tumor cell metastasis (Xiao et al., 2015). *CXCL9* and *CXCL10*, the ligands for *CXCR3*, are induced by IFN γ , and the corresponding genes were overexpressed by myeloid cells in colitis versus control subjects. However, *CXCL9* and *CXCL10* have been shown to be important for recruiting effector T cells to tumors, and blockade of either chemokine or IFN γ would be expected to have negative effects on anti-tumor immunity (Groom and Luster, 2011). In contrast, recruitment of lymphocytes into the gut is dependent on binding of the $\alpha 4\beta 7$ integrin to MadCAM on the gut endothelium (Neurath, 2019). Inhibition of $\alpha 4\beta 7$ integrin using the mAb vedolizumab is effective for treatment of IBD and appears to have efficacy in patients with +CPI colitis who failed to respond to corticosteroids (Abu-Sbeih et al., 2018). As expected, we observed expression of both genes (*ITGA4* and *ITGB7*) encoding the $\alpha 4\beta 7$ integrin receptor in T cells from multiple T cell clusters, including colitis-associated clusters. Retention of lymphocytes in the gut mucosa is dependent on $\alpha E\beta 7$ integrin (Neurath, 2019), and we observed high-level expression of the *ITGAE* gene in colitis-associated T cell clusters (in particular CD8⁺ T cells), suggesting that this integrin may be another potential therapeutic target. A mAb targeting the $\beta 7$ integrin chain shared by $\alpha 4\beta 7$ and $\alpha E\beta 7$ receptors is under clinical development (e.g., NCT02394028 and NCT02136069) and may be particularly effective for treatment of +CPI colitis.

The findings described here may have broad relevance for understanding the cellular and molecular mechanisms of other irAEs triggered by checkpoint blockade, in particular those occurring in epithelia infiltrated even in the healthy state by substantial populations of lymphocytes. Histological analysis of two cases with severe colitis following treatment with anti-PD-1 monotherapy demonstrated infiltration of the mucosa by CD8⁺ T cells and T-bet⁺ CD4⁺ T cells, consistent with our findings for patients who received combination CPI (Yoshino et al., 2019). In addition, fatal myocarditis in two melanoma patients treated with combination CPI was associated with robust infiltration of the myocardium by CD3⁺ and CD8⁺ T cells as well as macrophages (Johnson et al., 2016). These data provide a rich source for identification of therapeutic targets for +CPI colitis and other irAEs, as illustrated by the identified chemokines, cytokines, and cell surface receptors.

The findings described here may have broad relevance for understanding the cellular and molecular mechanisms of other irAEs triggered by checkpoint blockade, in particular those occurring in epithelia infiltrated even in the healthy state by substantial populations of lymphocytes. Histological analysis of two cases with severe colitis following treatment with anti-PD-1 monotherapy demonstrated infiltration of the mucosa by CD8⁺ T cells and T-bet⁺ CD4⁺ T cells, consistent with our findings for patients who received combination CPI (Yoshino et al., 2019). In addition, fatal myocarditis in two melanoma patients treated with combination CPI was associated with robust infiltration of the myocardium by CD3⁺ and CD8⁺ T cells as well as macrophages (Johnson et al., 2016). These data provide a rich source for identification of therapeutic targets for +CPI colitis and other irAEs, as illustrated by the identified chemokines, cytokines, and cell surface receptors.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead contact
 - Materials Availability
 - Data and Code Availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Patients and tissue samples

Figure 7. T Cell-Myeloid Cell Connectivity and Therapeutic Targets

(A) Analysis of chemokine receptor-ligand pairs across clusters from the CD45⁺ dataset (aggregated dataset from all patients). All shown interactions were statistically significant based on a permutation test, and arrows denote directionality from ligand to receptor (STAR Methods).

(B) Normalized gene expression for the indicated chemokine receptors in the CD45⁺ dataset.

(C) Normalized expression of the indicated chemokine genes in the myeloid sub-cluster (feature plot and violin plot for each cluster)

(D) Heatmap displaying Z score-normalized averaged expression of the indicated chemokine and chemokine receptor genes among total CD45⁺ cells, compared among patient groups. Adj. p values are shown.

(E) Violin plots displaying normalized expression of integrin genes among CD8 (top) and CD4 (bottom) clusters. *Adj. p = 10E−05–50, **Adj. p = 10E−50–100, ***Adj. p = 10E−100+.

(F) Analysis of cytokine receptor-ligand pairs across clusters from the CD45⁺ dataset as in (A).

(G) Heatmap showing Z score-normalized averaged expression of the indicated cytokine and cytokine receptor genes compared among patient groups. Expression is shown for T cell clusters (11–16) or the myeloid cluster (5) from the CD45⁺ dataset, as indicated. Adj. p values are shown.

(H and I) Single-cell gene set activity score for positive regulation of NLRP3 inflammasome expression for the myeloid sub-cluster (combined cells from all patients, H) and quantified for patient groups with two-sided Wilcoxon test (I). See also Figure S7.

- **METHOD DETAILS**
 - Preparation of single cell suspensions
 - Sorting of CD3+ and CD45+ MNC for scRNA-seq
 - Cell preparation for 5' barcoded scRNA-seq
 - Library preparation for scRNA-seq
 - Sequencing of scRNA-seq libraries
 - Antibody staining for spectral flow cytometry
 - Spectral flow cytometry analysis
 - Multiplex immunofluorescence of FFPE colon biopsies
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
 - Flow cytometry data analysis
 - Pre-processing of single cell RNA-seq data
 - Identification of cell clusters
 - Annotation of cell clusters and data visualization
 - Identification of colitis-associated clusters
 - Differential expression analysis
 - Functional enrichment analysis
 - RNA velocity analysis
 - T cell receptor data analysis
 - Cluster relationships of clonally expanded T cells
 - Calculation of gene set activity score
 - Evaluation of co-activation potentiality
 - Ligand-receptor expression and cell interactions

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.cell.2020.06.001>.

ACKNOWLEDGMENTS

This work was supported by a Team Award from the American Cancer Society (MRAT-18-113-01), the Melanoma Research Alliance (597698 to K.W.W., S.K.D., M.D., G.-C.Y., and R.J.S.), NIH grants R01 CA238039 (to K.W.W.), P01 CA163222 (to K.W.W. and F.S.H.), and T32CA207021 (to A.M.L. and K.W.W.); National Institutes of Health Mentored Clinical Scientist Development Award 1K08DK114563-01 (to M.D.); and the American Gastroenterological Association Research Scholars Award (to M.D.). We would like to thank all of the patients who participated in this study and the nursing and surgical technicians from the MGH endoscopy unit who provided care for the patients and made safe biopsy collection feasible. We would further like to thank Md Aladdin Bhuiyan, Elisa Bello, Patrick Lenehan, and Max Heckler for providing specific technical assistance and Ruben Dries for helpful discussions. We thank Susannah Phillips, J. Harrison Carmichael, and Dennie Frederick for help with clinical sample collection. We thank the Center for Cancer Genome Discovery (DFCI) for sequencing of scRNA-seq libraries.

AUTHOR CONTRIBUTIONS

A.M.L., S.K.D., M.D., and K.W.W. designed the study. A.M.L. processed tissue biopsies, generated scRNA-seq gene expression libraries, and performed flow cytometry studies. S.S. and G.-C.Y. performed computational analyses. H.L.W. and J.A.N. performed immunofluorescence studies of tissue sections. M.D. supervised the clinical aspects of the study, enrolled patients, and performed endoscopic exams. T.S., K.S., M.M., and P.B. collected patient consent for the study and assisted with sample collection. F.S.H., O.R., R.J.S., and G.M.B. contributed to the clinical aspects of the study design. A.M.L., S.S., M.D., and K.W.W. wrote the paper with input from all authors.

DECLARATION OF INTERESTS

K.W.W. serves on the scientific advisory board of TCR2 Therapeutics, T-Scan Therapeutics, and Nextechinvest and receives sponsored research funding

from Novartis. He is a scientific co-founder of Immunitas Therapeutics. M.D. receives research funding from Novartis and is on the Scientific Advisory Board for Neoleukin Therapeutics. S.K.D. receives research funding from Novartis, Bristol-Myers Squibb, and Eli Lilly. F.S.H. receives research funding from Bristol-Myers Squibb and Novartis; he also consults for Merck, EMD Serono, Novartis, Takeda, Genentech/Roche, Compass Therapeutics, Apricity, Aduro, Sanofi, Pionyr, 7 Hills Pharma, Verastem, Torque, Rheos Kairos, Psioxus Therapeutics, Amgen, and Pieris Pharmaceutical. O.R. receives research support from Merck and is a speaker for activities supported by educational grants from BMS and Merck. He is a consultant for Merck, Celgene, Five Prime, GSK, GFK, Bayer, Roche/Genentech, Puretech, Imvax, and Sobi. In addition, he has patent "Methods of using pembrolizumab and trebananib" pending. J.A.N. has a provisional patent application for spatial quantification of immune cell infiltration in the tumor microenvironment. R.J.S. has received research funding from Merck and Amgen.

Received: January 25, 2020

Revised: April 10, 2020

Accepted: May 29, 2020

Published: June 29, 2020

REFERENCES

- Abu-Sbeih, H., Ali, F.S., Alsaadi, D., Jennings, J., Luo, W., Gong, Z., Richards, D.M., Charabaty, A., and Wang, Y. (2018). Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. *J. Immunother. Cancer* 6, 142.
- Aibar, S., González-Blas, C.B., Moerman, T., Huynh-Thu, V.A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.C., Geurts, P., Aerts, J., et al. (2017). SCENIC: single-cell regulatory network inference and clustering. *Nat. Methods* 14, 1083–1086.
- Aran, D., Looney, A.P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R.P., Wolters, P.J., Abate, A.R., et al. (2019). Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat. Immunol.* 20, 163–172.
- Arbour, K.C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W.V., Hendriks, L.E.L., et al. (2018). Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. *J. Clin. Oncol.* 36, 2872–2878.
- Badran, Y.R., Cohen, J.V., Brastianos, P.K., Parikh, A.R., Hong, T.S., and Dougan, M. (2019). Concurrent therapy with immune checkpoint inhibitors and TNF α blockade in patients with gastrointestinal immune-related adverse events. *J. Immunother. Cancer* 7, 226.
- Becht, E., McInnes, L., Healy, J., Dutertre, C.A., Kwok, I.W.H., Ng, L.G., Ginhoux, F., and Newell, E.W. (2018). Dimensionality reduction for visualizing single-cell data using UMAP. *Nat. Biotechnol.* 37, 38–44.
- Blondel, V.D., Guillaume, J.-L., Lambiotte, R., and Lefebvre, E. (2008). Fast unfolding of communities in large networks. *J. Stat. Mech.* 2008, P10008.
- Cepek, K.L., Shaw, S.K., Parker, C.M., Russell, G.J., Morrow, J.S., Rimm, D.L., and Brenner, M.B. (1994). Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. *Nature* 372, 190–193.
- Coutzac, C., Adam, J., Soularue, E., Collins, M., Racine, A., Mussini, C., Bosselli, L., Kamsukom, N., Mateus, C., Charrier, M., et al. (2017). Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. *J. Crohn's Colitis* 11, 1238–1246.
- Curran, M.A., Montalvo, W., Yagita, H., and Allison, J.P. (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. *Proc. Natl. Acad. Sci. USA* 107, 4275–4280.
- Dougan, M. (2017). Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. *Front. Immunol.* 8, 1547.

- Dougan, M., and Pietropaolo, M. (2020). Time to dissect the autoimmune etiology of cancer antibody immunotherapy. *J. Clin. Invest.* *130*, 51–61.
- Downey, S.G., Klapper, J.A., Smith, F.O., Yang, J.C., Sherry, R.M., Royal, R.E., Kammula, U.S., Hughes, M.S., Allen, T.E., Levy, C.L., et al. (2007). Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. *Clin. Cancer Res.* *13*, 6681–6688.
- Faje, A.T., Lawrence, D., Flaherty, K., Freedman, C., Fadden, R., Rubin, K., Cohen, J., and Sullivan, R.J. (2018). High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. *Cancer* *124*, 3706–3714.
- Foulds, K.E., Zenewicz, L.A., Shedlock, D.J., Jiang, J., Troy, A.E., and Shen, H. (2002). Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. *J. Immunol.* *168*, 1528–1532.
- Geukes Foppen, M.H., Rozeman, E.A., van Wilpe, S., Postma, C., Snaebjornsson, P., van Thienen, J.V., van Leerdam, M.E., van den Heuvel, M., Blank, C.U., van Dieren, J., and Haanen, J.B.A.G. (2018). Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. *ESMO Open* *3*, e000278.
- Groom, J.R., and Luster, A.D. (2011). CXCR3 ligands: redundant, collaborative and antagonistic functions. *Immunol. Cell Biol.* *89*, 207–215.
- Grover, S., and Srivastava, A. (2019). Lymphocytic colitis-like pattern of mucosal injury and the challenges in diagnosing cancer immunotherapy-related toxicity. *Cancer* *125*, 1768–1770.
- Gu, Z., Gu, L., Eils, R., Schlesner, M., and Brors, B. (2014). circlize Implements and enhances circular visualization in R. *Bioinformatics* *30*, 2811–2812.
- Herold, M.J., McPherson, K.G., and Reichardt, H.M. (2006). Glucocorticoids in T cell apoptosis and function. *Cell. Mol. Life Sci.* *63*, 60–72.
- Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. *N. Engl. J. Med.* *363*, 711–723.
- Huang, B., Chen, Z., Geng, L., Wang, J., Liang, H., Cao, Y., Chen, H., Huang, W., Su, M., Wang, H., et al. (2019). Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways. *Cell* *179*, 1160–1176.e24.
- Hughes, M.S., Molina, G.E., Chen, S.T., Zheng, H., Deshpande, V., Fadden, R., Sullivan, R.J., and Dougan, M. (2019). Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. *J. Immunother. Cancer* *7*, 292.
- Ilicic, T., Kim, J.K., Kolodziejczyk, A.A., Bagger, F.O., McCarthy, D.J., Marioni, J.C., and Teichmann, S.A. (2016). Classification of low quality cells from single-cell RNA-seq data. *Genome Biol.* *17*, 29.
- Johnson, D.B., Balko, J.M., Compton, M.L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M.R., Bloomer, T.L., et al. (2016). Fulminant Myocarditis with Combination Immune Checkpoint Blockade. *N. Engl. J. Med.* *375*, 1749–1755.
- Joosse, M.E., Nederlof, I., Walker, L.S.K., and Samsom, J.N. (2019). Tipping the balance: inhibitory checkpoints in intestinal homeostasis. *Mucosal Immunol.* *12*, 21–35.
- Koch, M.A., Tucker-Heard, G., Perdue, N.R., Killebrew, J.R., Urdahl, K.B., and Campbell, D.J. (2009). The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. *Nat. Immunol.* *10*, 595–602.
- Korotkevich, G., Sukhov, V., and Sergushichev, A. (2019). Fast gene set enrichment analysis. *bioRxiv*. <https://doi.org/10.1101/060012>.
- Kuehn, H.S., Ouyang, W., Lo, B., Deenick, E.K., Niemela, J.E., Avery, D.T., Schickel, J.N., Tran, D.Q., Stoddard, J., Zhang, Y., et al. (2014). Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. *Science* *345*, 1623–1627.
- Kumar, B.V., Ma, W., Miron, M., Granot, T., Guyer, R.S., Carpenter, D.J., Senda, T., Sun, X., Ho, S.H., Lerner, H., et al. (2017). Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. *Cell Rep.* *20*, 2921–2934.
- La Manno, G., Soldatov, R., Zeisel, A., Braun, E., Hochgerner, H., Petukhov, V., Lidschreiber, K., Kastrioti, M.E., Lönnerberg, P., Furlan, A., et al. (2018). RNA velocity of single cells. *Nature* *560*, 494–498.
- Langer, V., Vivi, E., Regensburger, D., Winkler, T.H., Waldner, M.J., Rath, T., Schmid, B., Skottke, L., Lee, S., Jeon, N.L., et al. (2019). IFN- γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption. *J. Clin. Invest.* *129*, 4691–4707.
- Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N. Engl. J. Med.* *373*, 23–34.
- Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J.P., and Tamayo, P. (2015). The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst.* *1*, 417–425.
- Lord, J.D., Hackman, R.C., Moglebust, A., Thompson, J.A., Higano, C.S., Chielens, D., Steinbach, G., and McDonald, G.B. (2010). Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. *Dig. Dis. Sci.* *55*, 1396–1405.
- Maloy, K.J., and Powrie, F. (2011). Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature* *474*, 298–306.
- Martin, J.C., Chang, C., Boschetti, G., Ungaro, R., Giri, M., Grout, J.A., Gettler, K., Chuang, L.S., Nayar, S., Greenstein, A.J., et al. (2019). Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. *Cell* *178*, 1493–1508.e20.
- Masopust, D., and Soerens, A.G. (2019). Tissue-Resident T Cells and Other Resident Leukocytes. *Annu. Rev. Immunol.* *37*, 521–546.
- McGinnis, C.S., Murrow, L.M., and Gartner, Z.J. (2019). DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst.* *8*, 329–337.e4.
- McInnes, L., Healy, J., and Melville, J. (2018). UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. *arXiv*, 1802.03426. <https://arxiv.org/abs/1802.03426>.
- McLane, L.M., Abdel-Hakeem, M.S., and Wherry, E.J. (2019). CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. *Annu. Rev. Immunol.* *37*, 457–495.
- Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009). Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. *Immunity* *30*, 899–911.
- Neurath, M.F. (2014). Cytokines in inflammatory bowel disease. *Nat. Rev. Immunol.* *14*, 329–342.
- Neurath, M.F. (2019). Targeting immune cell circuits and trafficking in inflammatory bowel disease. *Nat. Immunol.* *20*, 970–979.
- Pijuan-Sala, B., Griffiths, J.A., Guibentif, C., Hiscock, T.W., Jawaid, W., Calero-Nieto, F.J., Mulas, C., Ibarra-Soria, X., Tyser, R.C.V., Ho, D.L.L., et al. (2019). A single-cell molecular map of mouse gastrulation and early organogenesis. *Nature* *566*, 490–495.
- Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., Linette, G.P., Meyer, N., Giguere, J.K., Agarwala, S.S., et al. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N. Engl. J. Med.* *372*, 2006–2017.
- Postow, M.A., Sidlow, R., and Hellmann, M.D. (2018). Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. *N. Engl. J. Med.* *378*, 158–168.
- Ridker, P.M., MacFadyen, J.G., Thuren, T., Everett, B.M., Libby, P., and Glynn, R.J.; CANTOS Trial Group (2017). Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet* *390*, 1833–1842.
- Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* *13*, 2498–2504.

- Sharma, A., Subudhi, S.K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J.P., Ribas, A., and Sharma, P. (2019). Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3⁺ Regulatory T Cells (Tregs) in Human Cancers. *Clin. Cancer Res.* 25, 1233–1238.
- Sherwood, A.M., Desmarais, C., Livingston, R.J., Andriesen, J., Haussler, M., Carlson, C.S., and Robins, H. (2011). Deep sequencing of the human TCR γ and TCR β repertoires suggests that TCR β rearranges after $\alpha\beta$ and $\gamma\delta$ T cell commitment. *Sci. Transl. Med.* 3, 90ra61.
- Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J.Y., Yagita, H., Wolchok, J.D., et al. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. *J. Exp. Med.* 210, 1695–1710.
- Smillie, C.S., Biton, M., Ordovas-Montanes, J., Sullivan, K.M., Burgin, G., Graham, D.B., Herbst, R.H., Rogel, N., Slyper, M., Waldman, J., et al. (2019). Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. *Cell* 178, 714–730.e22.
- Solomon, B.L., and Garrido-Laguna, I. (2018). TIGIT: a novel immunotherapy target moving from bench to bedside. *Cancer Immunol. Immunother.* 67, 1659–1667.
- Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., 3rd, Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell Data. *Cell* 177, 1888–1902.e21.
- Suo, S., Zhu, Q., Saadatpour, A., Fei, L., Guo, G., and Yuan, G.C. (2018). Revealing the Critical Regulators of Cell Identity in the Mouse Cell Atlas. *Cell Rep.* 25, 1436–1445.e3.
- Szabo, P.A., Miron, M., and Farber, D.L. (2019). Location, location, location: Tissue resident memory T cells in mice and humans. *Sci. Immunol.* 4, 4.
- Walker, M.G., Volkmoth, W., Sprinzak, E., Hodgson, D., and Klingler, T. (1999). Prediction of gene function by genome-scale expression analysis: prostate cancer-associated genes. *Genome Res.* 9, 1198–1203.
- Wang, J., Ioan-Facsinay, A., van der Voort, E.I., Huizinga, T.W., and Toes, R.E. (2007). Transient expression of FOXP3 in human activated nonregulatory CD4⁺ T cells. *Eur. J. Immunol.* 37, 129–138.
- West, N.R., Hegazy, A.N., Owens, B.M.J., Bullers, S.J., Linggi, B., Buonocore, S., Coccia, M., Görtz, D., This, S., Stockenhuber, K., et al.; Oxford IBD Cohort Investigators (2017). Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. *Nat. Med.* 23, 579–589.
- Wickham, H. (2016). *ggplot2: elegant graphics for data analysis* (Springer).
- Xiao, G., Wang, X., Wang, J., Zu, L., Cheng, G., Hao, M., Sun, X., Xue, Y., Lu, J., and Wang, J. (2015). CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms. *Oncotarget* 6, 14165–14178.
- Yoshino, K., Nakayama, T., Ito, A., Sato, E., and Kitano, S. (2019). Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. *BMC Cancer* 19, 1019.
- Yost, K.E., Satpathy, A.T., Wells, D.K., Qi, Y., Wang, C., Kageyama, R., McNamara, K.L., Granja, J.M., Sarin, K.Y., Brown, R.A., et al. (2019). Clonal replacement of tumor-specific T cells following PD-1 blockade. *Nat. Med.* 25, 1251–1259.
- Zeissig, S., Petersen, B.S., Tomczak, M., Melum, E., Huc-Claustre, E., Dougan, S.K., Laerdahl, J.K., Stade, B., Forster, M., Schreiber, S., et al. (2015). Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. *Gut* 64, 1889–1897.
- Zhang, M.L., Neyaz, A., Patil, D., Chen, J., Dougan, M., and Deshpande, V. (2020). Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. *Histopathology* 76, 233–243.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-human CD3 PE-Dazzle 594 (Clone UCHT1)	Biolegend	Cat#300450; RRID:AB_2563618
Anti-human CD45 Pacific Blue (Clone HI30)	Biolegend	Cat#304022; RRID:AB_493655
Anti-human CD66b PE-Cy7 (Clone G10F5)	Biolegend	Cat#305116; RRID:AB_2566605
Anti-human CD15 APC (Clone HI98)	Biolegend	Cat#301908; RRID:AB_314200
Human TruStain FcX (Fc Receptor Blocking Solution)	Biolegend	Cat# 422302; RRID:AB_2818986
Anti-human TCR gamma/delta BV421 (Clone B1)	Biolegend	Cat#331218; RRID:AB_2562317
Anti-human CD14 BV510 (Clone M5E2)	Biolegend	Cat#301842; RRID:AB_2561946
Anti-human CD15 BV510 (Clone W6D3)	Biolegend	Cat#323028; RRID:AB_2563400
Anti-human CD64 BV510 (Clone 10.1)	BD Biosciences	Cat# 563459; RRID:AB_2738220
Anti-human CD163 BV510 (Clone GHI/61)	Biolegend	Cat# 333628; RRID:AB_2650632
Anti-human CD8a BV570 (Clone RPA-T8)	Biolegend	Cat#301038; RRID:AB_2563213
Anti-human CD103 BV605 (Clone Ber-ACT8)	Biolegend	Cat#350217; RRID:AB_2564282
Anti-human TCR V α 7.2 BV785 (Clone 3C10)	Biolegend	Cat#351722; RRID:AB_2566042
Anti-human CD3 Alexa Fluor 532 (Clone UCHT1)	Thermo Fisher Scientific	Cat#58-0038-42; RRID:AB_11218675
Anti-human CD69 PE (Clone FN50)	Biolegend	Cat#310906; RRID:AB_314841
Anti-human CD161 PerCp-Cy5.5 (Clone HP-3G10)	Biolegend	Cat#339908; RRID:AB_2132862
Anti-human CD4 Alexa Fluor 700 (Clone RPA-T4)	Thermo Fisher Scientific	Cat#56-0049-42; RRID:AB_11219085
Anti-human Ki-67 Alexa Fluor 488 (Clone Ki-67)	Biolegend	Cat#350507; RRID:AB_10933085
Anti-human Granzyme B PE-CF594 (Clone GB11)	BD Biosciences	Cat#562462; RRID:AB_2737618
Anti-human CTLA-4 PE-Cy7 (Clone L3D10)	Biolegend	Cat#349914; RRID:AB_2563098
Anti-human FoxP3 APC (Clone 236A/E7)	Thermo Fisher Scientific	Cat#17-4777-42; RRID:AB_1080465
Anti-human CD3 Unconjugated (Clone F7.2.38)	Dako (Agilent)	Cat# M725429-2
Anti-human CD4 Unconjugated (Clone EP204)	Cell Marque	Cat# AC-0173
Anti-human FoxP3 Unconjugated (Clone 206D)	Biolegend	Cat#320102; RRID:AB_430881
Anti-human CD8 Unconjugated (Clone C8/144B)	Dako (Agilent)	Cat# M710301-2
Anti-human Ki-67 Unconjugated (Clone SP6)	Thermo Fisher Scientific	Cat# MA5-14520; RRID:AB_10979488
Anti-human Pan-Cytokeratin Unconjugated (Clone C11)	Dako (Agilent)	Cat# M351501-2
Anti-human Pan-Cytokeratin Unconjugated (Clone AE1/AE3)	Cell Signaling Technology	Cat# CST4545

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Anti-mouse and rabbit Opal Polymer HRP	Akoya Biosciences	Cat# ARH1001EA
Biological Samples		
Fresh colon and rectum biopsies obtained following informed consent for IRB-approved studies	Massachusetts General Hospital, Brigham and Women's Hospital/Dana-Farber Cancer Institute	IRB# DF/HCC 15-302, 18-080, 11-181, 18-498
Paraffin-embedded formalin fixed slides, prepared from colon biopsy samples obtained following informed consent on an IRB-approved study	Massachusetts General Hospital	IRB# 15-302
Chemicals, Peptides, and Recombinant Proteins		
ACK red blood cell lysis buffer	Thermo Fisher Scientific	Cat# A1049201
DAPI	Akoya Biosciences	Cat# FP1490
Ultrapure Bovine Serum Albumin, RNase-free	Thermo Fisher Scientific	Cat# AM2616
Critical Commercial Assays		
Tumor Dissociation Kit, human	Miltenyi Biotec	Cat# 130-095-929
Zombie NIR Fixable Viability Kit	Biolegend	Cat#423106
eBioscience Foxp3 / Transcription Factor Staining Buffer Set	Thermo Fisher Scientific	Cat# 00-5523-00
OneComp eBeads Compensation Beads	Thermo Fisher Scientific	Cat# 01-1111-42
Antibody Diluent / Block	Akoya Biosciences	Cat# ARD1001EA
Target Retrieval Solution, Tris/EDTA	Dako (Agilent)	Cat# S236784-2
BOND Epitope Retrieval Solution	Leica Biosystems	Cat# AR9961
ProLong Gold Antifade	Thermo Fisher Scientific	Cat# P36935
Opal 540	Akoya Biosciences	Cat# FP1494001KT
Opal 520	Akoya Biosciences	Cat# FP1487001KT
Opal 570	Akoya Biosciences	Cat# FP1488001KT
Opal 620	Akoya Biosciences	Cat# FP1495001KT
Opal 650	Akoya Biosciences	Cat# FP1496001KT
Opal 690	Akoya Biosciences	Cat# FP1497001KT
10X Chromium Single Cell 5' Library & Gel Bead Kit	10X Genomics	Cat# 1000006
10X Chromium Single Cell A Chip Kit	10X Genomics	Cat# 1000152
10X Chromium Single Cell V(D)J Enrichment Kit, Human T Cell	10X Genomics	Cat# 1000005
10X Chromium Single Cell 5' Library Construction Kit	10X Genomics	Cat#1 000020
High Sensitivity D5000 ScreenTape	Agilent	Cat# 5067-5592
High Sensitivity D5000 Reagents	Agilent	Cat# 5067-5593
High Sensitivity D1000 ScreenTape	Agilent	Cat# 5067-5584
High Sensitivity D1000 Reagents	Agilent	Cat# 5067-5585
Deposited Data		
MSigDB hallmark and GO gene sets	Liberzon et al., 2015	https://www.gsea-msigdb.org/gsea/msigdb/index.jsp
Single cell RNA-seq data and TCR sequencing data	This paper	GEO: GSE144469
Oligonucleotides		
TRGC outer primer TGGCACCGTTAACCAGCTAA	This paper	N/A

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
TRDC outer primer CGTGTTGAACTGAACATGTCAC	This paper	N/A
TRGC inner primer GGTATGTTCCAGCCTTCTGG	This paper	N/A
TRDC inner primer GTTCCATTTTTCATGACAAAAACGG	This paper	N/A
Forward primer round 1 AATGATACGGCGACCACCGAGATCTA CACTCTTCCCTACACGACGCTC	10X Genomics 5' VDJ assay configuration	N/A
Forward primer round 2 AATGATACGGCGACCACCGAGATCT	10X Genomics 5' VDJ assay configuration	N/A
Software and Algorithms		
FlowJo V10.4	Tree Star	RRID:SCR_008520
GraphPad Prism 8.4.1	GraphPad Software	RRID:SCR_002798
SnapGene (v5.0.7)	GSL Biotech	https://www.snapgene.com/
CellRanger (v3.02 and v3.1.0)	10X Genomics	https://support.10xgenomics.com/single-cell-gene-expression/software/downloads/latest
Seurat (v3.1.0, R package)	Stuart et al., 2019	https://github.com/satijalab/seurat
DoubletFinder (v2.0.2, R package)	McGinnis et al., 2019	https://github.com/chris-mcginnis-ucsf/DoubletFinder
fgsea (v1.11.1, R package)	Korotkevich et al., 2019	https://bioconductor.org/packages/release/bioc/html/fgsea.html
AUCell (v1.7.2, R package)	Aibar et al., 2017	https://bioconductor.org/packages/release/bioc/html/AUCell.html
SingleR (v0.99.10, R package)	Aran et al., 2019	https://bioconductor.org/packages/release/bioc/html/SingleR.html
ggplot2 (v3.2.1, R package)	Wickham, 2016	https://ggplot2.tidyverse.org
circlize (v0.4.8, R package)	Gu et al., 2014	https://cran.r-project.org/web/packages/circlize/index.html
Uniform Manifold Approximation and Projection (UMAP)	McInnes et al., 2018	https://github.com/lmcinnes/umap
R (v3.6.1)	The R Foundation	https://www.r-project.org
Cytoscape (v3.5.1)	Shannon et al., 2003	https://www.cytoscape.org/
Velocyto (v0.17.17)	La Manno et al., 2018	http://velocyto.org

RESOURCE AVAILABILITY**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, K.W.W. (Kai_Wucherpfennig@dfci.harvard.edu).

Materials Availability

This study did not generate new unique reagents.

Data and Code Availability

The datasets generated during this study are available at the Gene Expression Omnibus under accession number GEO: GSE144469.

EXPERIMENTAL MODEL AND SUBJECT DETAILS**Patients and tissue samples**

Biopsy samples were obtained from CPI-treated melanoma patients undergoing a diagnostic endoscopy procedure at Massachusetts General Hospital or Brigham and Women's Hospital/Dana-Farber Cancer Institute. Prior to the procedure, patients provided

informed consent for collection of additional research biopsies, in accordance with IRB-approved protocols (DF/HCC 15-302, 18-080, 11-181, and 18-498). Histological analysis of biopsies was performed following endoscopy, at which time patients were assigned to either +CPI colitis or +CPI no colitis patient groups. As an additional control group, healthy age-matched adults were consented prior to a regular screening colonoscopy procedure (DF/HCC 15-302 and 18-080). Subjects included both males and females spanning an age range of 21-78 years, and details on individual patients can be found in [Table S1](#). In all cases, biopsies were obtained during endoscopy using a standard-of-care forceps, spanning the regions from the descending colon, sigmoidal colon, and rectum; for two patients, C2 and NC2, biopsies from the ascending colon were also collected. Typically, 2-6 biopsies from each region were separately allocated into DMEM media and transported on ice to the lab for immediate tissue dissociation. For some patients ($n = 4$ control, $n = 1$ +CPI no colitis), descending, sigmoid, and rectum biopsies were collected as a single pool rather than separately from each region.

METHOD DETAILS

Preparation of single cell suspensions

When biopsies were collected from multiple subregions, we combined main colon biopsies (descending colon for all patients except for C2 and NC2, from whom ascending biopsies were also combined) and sigmoid plus rectum biopsies to make two pools. Biopsies were transferred to 6 cm tissue culture dishes placed on ice and cut into < 1 mm pieces with a razor blade while immersed in a small volume in DMEM (ThermoFisher Scientific # 11995073) to preserve tissue hydration. Tissue pieces were centrifuged (400 g for 5 min at 4°C for all centrifuge steps) and resuspended in 2 mL of collagenase-containing enzymatic digestion solution prepared according to manufacturer's instructions (Miltenyi Human Tumor Dissociation Kit #30-095-929). Biopsies were incubated at 37°C for 25-30 min with mixing using a P1000 pipet tip (10-minute intervals) and intervening gentle vortexing (2-5-minute intervals). Digestion produced a nearly uniform single cell suspension which was passed through a 70 μ m nylon mesh filter. Filtered cell suspensions were centrifuged and resuspended in 3 mL ACK red blood cell lysis buffer (GIBCO #A1049201) for 1 minute at RT, then immediately diluted with 10 mL of PBS buffer containing 0.5% FBS (Life Technologies# 10437028) and 1 mM EDTA to halt osmotic stress. Cells were centrifuged and subsequently resuspended in Zombie NIR (Biolegend #423106) viability dye solution (1:500 in PBS), followed by 15 min incubation at RT in the dark. Cells were counted with a hemocytometer, generally yielding $> 100,000$ live cells per individual biopsy. Following viability dye staining, cells were allocated for sorting/single-cell RNA-seq or spectral flow cytometry.

Sorting of CD3+ and CD45+ MNC for scRNA-seq

For patients with biopsies spanning multiple regions, descending colon and sigmoid-rectum cell suspensions were combined in equal numbers to provide an aggregate analysis of the lower colon. Cells stained with viability dye ($0.4-0.6 \times 10^6$) were resuspended in 100 μ L of FACS wash buffer (FWB; PBS, 2%FBS, 1 mM EDTA) with the addition of the following antibodies: TruStain FcX (Biolegend 422302), CD3-PE/Dazzle (Biolegend 300450), CD45-Pacific Blue (Biolegend 304022), CD66b-PE/Cy7 (Biolegend 305116) and CD15-APC (Biolegend 301908). Cells were incubated on ice for 20 minutes, washed with 1 mL FWB, and then resuspended in 500 μ L FWB for sorting on a FACS Aria II or III (BD Biosciences). For the majority of samples, $12-15 \times 10^3$ live CD45⁺CD66b⁻ mononuclear cells (MNC) cells and CD3⁺ cells (pre-gated on live MNC) were separately sorted into T cell media (RMPI + 10% FBS) and immediately transferred to ice. CD66b⁺ granulocytes were excluded from the analysis because these cells interfere with scRNA-seq using the 10X Genomics protocol.

Cell preparation for 5' barcoded scRNA-seq

Sorted cells were centrifuged and washed with PBS containing 0.05% RNase-free BSA (ThermoFisher Scientific #AM2616), leaving a final volume of < 31 μ L. CD3⁺ and CD45⁺ MNC cells were loaded into separate channels of a Single Cell Chip A, along with reverse transcriptase reagent mixture and 5' gel beads according to manufacturer's protocol (10X Genomics). Chips were loaded into the 10X Genomics Chromium Controller for single-cell partitioning. Emulsions were immediately recovered from the chip and incubated in a deep-well block Thermocycler (Bio-Rad Laboratories) for the reverse transcription reaction.

Library preparation for scRNA-seq

All steps from cDNA isolation to library preparation were completed as per manufacturer's protocol. Isolated cDNA was amplified (14 cycles), after which cDNA was allocated for TCR enrichment/library preparation with the Chromium Single Cell V(D)J TCR kit, or for preparation of a gene expression library. cDNA and library quality was evaluated using the D5000 and D1000 high-sensitivity kits on a 2200 TapeStation system (Agilent).

We also prepared custom $\gamma\delta$ TCR-enriched libraries. From amplified cDNA, we performed 2 rounds of PCR enrichment of $\gamma\delta$ TCR genes used nested primers annealing to TRGC1/2 and TRDC (1 μ M each in reaction). Forward primers were the same as used for $\alpha\beta$ TCR enrichment as described in the manufacturer's technical protocol: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTA CACGACGCTC for the first-round PCR and AATGATACGGCGACCACCGAGATCT for the second-round PCR, both at 2 μ M. PCR reaction conditions, purification steps, and library preparation were performed according to the manufacturer's protocol for TCR V(D)J enrichment.

Sequencing of scRNA-seq libraries

CD3⁺ T cell gene expression libraries were sequenced on the Illumina HiSeq 4000 platform with 150 bp paired-end read configuration. CD45⁺ MNC libraries were sequenced either on the Illumina HiSeq 4000 platform with 150 bp paired-end read configuration or the HiSeq 2500 platform on rapid run mode. We obtained > 30,000 reads per cell for all samples, which was particularly important with CD45⁺ libraries for sufficient sampling of non-immunoglobulin genes given the high plasma B cell count. TCR V(D)J libraries were sequenced on the Illumina MiSeq (V2 flowcell), HiSeq 2500, or HiSeq 4000 platform, all on 150 bp paired-end read configuration.

Antibody staining for spectral flow cytometry

Viability dye-stained cells ($0.1-1 \times 10^6$) from the combined descending and sigmoid-rectum colon cell suspensions were centrifuged and resuspended in 50-100 μ L FWB to a density of $0.2-1 \times 10^7$ cells/mL in V-bottom plates. The following antibodies for cell surface epitope staining were added, and cells were incubated for 30 min at 4°C in the dark.

Following incubation, cells were washed twice with 150-200 μ L FWB before proceeding to intracellular staining. Cells were then fixed and permeabilized with the FoxP3/transcription factor buffer staining set (eBioscience) for 20 min at RT. Cells were washed twice with 1x permeabilization buffer before proceeding to intracellular staining with the following antibodies diluted in 1X permeabilization buffer.

Cells were stained for 20 min at RT in the dark, and then washed twice with 1X permeabilization buffer. Stained cells were resuspended in 300 μ L FWB and stored at 4°C protected from light until analysis within 48 hours.

Spectral flow cytometry analysis

Stained cells were passed through a 40 μ m filter and analyzed with a Sony SP6800 Spectral Analyzer. Single-color controls for spectral unmixing, using the identical antibodies as for analysis, were acquired using OneComp eBeads (ThermoFisher 01-1111-41) and fixed when applicable to match experimental conditions. The single-color control for Zombie NIR viability dye was acquired with PBMCs. Data were analyzed using FlowJo (Tree Star) version 10.4. Gating was confirmed with fluorescence-minus-one (FMO) controls from patient biopsy cell suspensions for low-density antigens, or a mixture of activated PBMC and Caco-2 colon cells for highly expressed antigens given the limited number of cells available from biopsies.

For cases (six from each patient group) with separately collected biopsies from multiple regions, we stained and analyzed descending colon (in 2 cases also including ascending colon) and sigmoid plus rectum separately. There were no significant regional variations in T cell populations, thus for analysis we used an average of these regions for comparison to patients from whom regional biopsies had been combined during initial collection.

Flow analysis included 3 additional patients not included in the scRNA-seq analysis. These comprised one +CPI no colitis patient and two healthy control subjects. Analysis of samples was performed over a 14-month period, and changes were made to the antibody panel after the initial patients to enable validation of key findings from the scRNA-seq data analysis. For patients C1 and C2, anti-Ki-67 and anti-CD103 were not included in the panel. For patients C3, NC1, NC2, and NC3, anti-Ki67 was not included in the panel. For patients C1 and C2, FITC-conjugated anti-CTLA-4 was used, which could not be clearly resolved during analysis and was exchanged with Pe-Cy7-conjugated anti-CTLA-4. These variations are reflected in sample numbers for corresponding flow analyses shown in the figures. Mean fluorescence intensities for parameters were only compared among patients with identical antibody panels and instrument configurations.

Multiplex immunofluorescence of FFPE colon biopsies

Sections from formalin-fixed paraffin-embedded tissue were cut at a thickness of 4 μ m, de-paraffinized in xylene and rehydrated through a graded alcohol series. Antigen retrieval using EDTA (Dako, S2367) was performed at 120°C for 20 minutes using a bench-top thermal processor (Electron Microscopy Services, 62706). Subsequent multiplex immunofluorescence staining was performed using a Leica BOND RX automated staining instrument (Leica Biosystems). Following protein block (ARD1001EA, Akoya Biosciences), primary antibodies (anti-CD3, Dako M7254; anti-CD4, Cell Marque EP204; anti-FOXP3, BioLegend 206D; anti-CD8, Dako M7103; anti-Ki67, ThermoFisher MA5-14520; Pan-cytokeratin, Dako M3515 and Cell Signaling CST4545) were each sequentially applied for 1 hour at room temperature, followed by a 10 minute incubation with a secondary antibody (ARH1001EA, Akoya Biosciences) and subsequent detection via tyramide-signal amplification and an Opal fluorophore for 10 minutes (CD3 Opal 540; CD4 Opal 520; FOXP3 Opal 570; CD8 Opal 650; Ki67 Opal 690 and Pan-cytokeratin Opal 620). After each round of detection, heat-induced epitope retrieval was performed on the autostainer using sodium citrate, pH 6 (Leica Biosystems, AR9961). After the final immunofluorescence staining round, DAPI (Akoya Biosciences, FP1490) was applied for 10 minutes. Coverslips were mounted using ProLong Gold Antifade (ThermoFisher Scientific, P36935). Whole slide overview images at 10x magnification were obtained using

Primers for $\gamma\delta$ TCR-enriched libraries

	TRGC1/2	TRDC
Outer primer (round 1)	TGGCACCGTTAACCAGCTAA	CGTGTGAACGAAACATGTCAC
Inner primer (round 2)	GGTATGTTCCAGCCTTCTGG	GTTCCATTTTTTCATGACAAAAACGG

Flow cytometry antibodies - surface staining

Reagent	Dilution	Supplier	Catalog Number
BV421 anti- $\gamma\delta$ TCR	1:20	Biolegend	331218
Pacific Blue anti-CD45	1:40	Biolegend	304022
BV510 anti-CD14, CD15, CD64, CD163 (Dump mixture)	1:80 each	Biolegend, BD	301842, 323028, 563459, 333628
BV570 anti-CD8 α	1:40	Biolegend	301038
BV605 anti-CD103	1:40	Biolegend	350217
BV785 anti-V α 7.2 TCR	1:20	Biolegend	351722
Alexa Fluor 532 anti-CD3	1:40	eBioscience	58-0038-42
PE anti-CD69	1:40	Biolegend	310906
PerCP-Cy5.5 anti-CD161	1:20	Biolegend	339908
Alexa Fluor 700 anti-CD4	1:20	eBioscience	56-0049-42

a Vectra 3.0 multispectral imaging system (Akoya Biosciences) and were used to select representative regions for multispectral imaging at 20x. Following generation of a spectral library using single color and unstained controls, multispectral unmixing was performed using the inForm software package (Akoya Biosciences, v2.4).

QUANTIFICATION AND STATISTICAL ANALYSIS

Flow cytometry data analysis

Statistical analyses of flow cytometry data were performed with Prism 8.4.1 (GraphPad). The number of *n*, which represents the number of individual patients analyzed, is shown in the figure legends with details in [Table S5](#). The Bartlett's test for equal variances was applied to the datasets to determine whether the standard deviations among comparison groups were significantly similar, informing which analyses were appropriate. The statistical method for each analysis is shown in the figure legends, and all analyses were corrected for multiple comparisons when appropriate. The mean and standard deviation is displayed in all plots * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

Pre-processing of single cell RNA-seq data

Raw single-cell RNA-seq data were processed using 10X Genomics Cell Ranger (v3.0.2), including demultiplexing the FASTQ reads, aligning them to the human reference genome (GRCh38, v3.0.0, from 10X Genomics), and counting the unique molecular identifier (UMI) (by using "cellranger count" function). All patient samples from each dataset were then aggregated by using the "cellranger aggr" function without depth normalization. As a result, a digital cell by gene expression matrix was generated, containing the number of UMIs for each gene detected in each cell. In addition, we carried out a number of steps to filter out poor quality data. First, we removed cells with high mitochondrial gene expression because damaged and dead cells often exhibit extensive mitochondrial contamination ([Ilicic et al., 2016](#)). Specifically, we fit the expression level of mitochondrial genes by using a median-centered median absolute deviation (MAD)-variance normal distribution, and then removed the cells with significantly higher expression levels than expected (determined by Benjamini-Hochberg corrected $p < 0.01$, for CD3+ dataset: 11.13%; for CD45+ dataset: 13.33%) ([Pijuan-Sala et al., 2019](#)). Second, we removed cells for which less than 200 genes were detected. Third, we identified and removed potential doublets by using DoubletFinder (v2.0.2), using 92.5th percentile of the doublet score as cutoff ([McGinnis et al., 2019](#)). In the end, we retained a total of 68,728 and 51,652 single cells for the CD3+ and CD45+ cell datasets, respectively.

Identification of cell clusters

The processed whole gene expression matrix with all selected cells was fed to Seurat (v3.1.0, R package) for downstream analyses ([Stuart et al., 2019](#)). Briefly, only genes expressed in more than 10 cells were kept, and the UMI count matrix was normalized by using 'NormalizeData' function, in which the number of UMI for each gene was divided by the total number of UMI in each cell and multiplied

by a scale factor of 10,000, followed by adding a pseudocount 1 for each gene and natural-log transformation. Based on the normalized gene expression matrix, 2,000 highly variable genes were identified by using the 'FindVariableFeatures' function with the 'vst'

Flow cytometry antibodies - intracellular staining

Reagent	Dilution	Supplier	Catalog Number
Alexa Fluor 488 anti-Ki67	1:20	Biolegend	350507
PE/CF594 anti-Granzyme B	1:50	BD	562462
PE/Cy-7 anti-CTLA-4	1:20	Biolegend	349914
APC anti-FoxP3	1:20	eBioscience	17-4777-42

method for both CD3+ and CD45+ datasets. In order to avoid the dominant effect of T cell receptor variable genes, as these genes usually show very high expression level in subpopulations of cells, in the determination of T cell clusters, TCR genes (*TRAV*, *TRBV*, *TRDV* and *TRGV* genes) were removed from the clustering analysis of the CD3+ dataset. In addition to the T cell receptor variable genes, the immunoglobulin variable (IG[X]V genes) genes were also removed from the highly variable genes in CD45+ dataset in clustering analysis. 'ScaleData' function was then used to scale and center the gene expression matrix after regressing out the heterogeneity associated with the mitochondrial contamination. To perform the clustering analysis, the first 20 principal components were selected for constructing the shared nearest neighbor (SNN) graph by using 'FindNeighbors' function, and then Louvain clustering algorithm was used to group the cells into different clusters (Blondel et al., 2008). For the CD3+ dataset, we removed four small clusters which did not express T cell marker genes (*CD3D*, *CD3E* and *CD3G*) and performed the clustering analysis again based on the remaining cells (67,926 cells).

Annotation of cell clusters and data visualization

We used two complementary approaches to annotate the identities of different cell clusters: (1) we checked whether the well-studied marker genes of different immune cell types were in the top rank of differential expressed genes of query cluster and then assigned the most likely identity for each cell cluster; (2) applied an unbiased cell type recognition method named SingleR (v0.99.10, R package) (Aran et al., 2019), which leverages reference transcriptomic datasets of known cell types for annotation (Martin et al., 2019; Smillie et al., 2019). We first applied SingleR to determine if the predicted annotations for a query cluster based on different reference datasets were consistent, and then assigned this cluster as the predicted cell type annotation; alternatively, we checked which genes were in the top rank of differentially expressed gene list of this cluster. The uniform manifold approximation and projection (UMAP) was applied to visualize the single cell transcriptional profile in 2D space based on the SNN graph described above (Becht et al., 2018; McInnes et al., 2018). Other bar plots, boxplots, violin plots and heatmaps were generated by customized R code through ggplot2 (v3.2.1, R package) (Wickham, 2016).

To analyze CD3+ T cells in detail, we split the CD3+ T cell dataset into CD4+ and CD8+ T cell subsets according to the mutually exclusive expression of CD4 ($CD4 > 1$ and $CD8A < 1$) and CD8A ($CD4 < 1$ and $CD8A > 1$) genes (based on normalized expression), and then applied the pipelines as described above, with the modification that 1,500 highly variable genes were selected to identify, annotate and visualize the cell clusters. We also used the same steps to perform the sub-clustering analysis for the Treg cell cluster (from CD4+ subset) and myeloid cell cluster (from CD45+ cell dataset). In the CD8+ dataset, we observed slight patient-specific batch effects as evidenced by clusters containing cells from only a single patient or fraction of patients, likely caused by technical differences. To correct this, we regressed out the unwanted source of technical variation by implementing the 'ScaleData' function before cell clustering.

Identification of colitis-associated clusters

To make the number of cells from different patients in each cluster comparable in CD3+, CD45+ datasets and other subsets, we first normalized the number of cells for each patient to the median of patients' total number of cells. Then the percentages of cells from different patients were calculated in each cluster and the two-sided Wilcoxon test was applied to obtain the P values between control and colitis groups. The clusters with P value < 0.05 were assigned as colitis-associated clusters.

Differential expression analysis

Differentially expressed genes in different clusters were identified by 'FindAllMarkers' function (use default parameters but set min.pct as 0.3) in Seurat. We also calculated a cell-type specificity score based on our previously described Jensen-Shannon Divergence algorithm for each identified differentially expressed gene and visualized the top ranked genes in CD4+ and CD8+ subsets (Suo et al., 2018). In order to identify colitis-related differentially expressed genes in CD4+ or CD8+ subsets, we combined colitis-associated clusters together and then compared with other clusters by using 'FindMarkers' function in Seurat with default

parameters but set `min.pct` as 0.3 and `logfc.threshold` as 0. Within the myeloid cluster, we used the same approach but compared cells from the CPI colitis group with cells from control or +CPI no colitis groups to identify colitis-related genes.

Functional enrichment analysis

We used a fast per-ranked gene set enrichment analysis (GSEA) named `fgsea` (v1.11.1, R package) to perform functional enrichment analysis for colitis-related differentially expressed genes (Korotkevich et al., 2019). First we downloaded the hallmark gene sets from Molecular Signatures Database (MsigDB; <https://www.gsea-msigdb.org/gsea/msigdb/index.jsp>; Liberzon et al., 2015), and then fed each differentially expressed gene list together with averaged log (fold-change) of each gene and the hallmark gene sets to the 'fgsea' function (`minSize = 15`, `maxSize = 1000`, `nperm = 1000`). Finally, only hallmark gene sets with adjusted P value < 0.05 were selected as the functionally enriched biological states or processes.

RNA velocity analysis

RNA velocity is widely used to infer the directionality and future state of individual cells by distinguishing un-spliced and spliced mRNAs from single-cell RNA-seq data. To analyze the expression dynamics in CD8+ or CD4+ T cell subsets, we applied the `velocity` (v0.17.17, python package) to estimate the RNA velocity of single cells by distinguishing spliced and un-spliced mRNAs (La Manno et al., 2018). We first generated the individual loom file based on the output file of Cell Ranger for each patient sample and then merged all loom files together. Then we fed the merged loom files and the UMAP coordinates of single cells generated by Seurat to `velocity` and followed its analysis steps to finally project the RNA velocity vectors onto low-dimension embeddings.

T cell receptor data analysis

Raw T cell receptor (TCR) sequencing data were processed by using 10X Genomics Cell Ranger (v3.1.0). Briefly, FASTQ reads were aligned to human GRCh38 V(D)J reference genome (v3.1.0, from 10X Genomics) by using the "cellranger vdj" function, resulting in the assembly of V(D)J sequences and clonotypes (Yost et al., 2019). On average, 5,988 read pairs were detected per cell in each patient sample. 95.36% (and 98.61%, respectively) of CD3+ cells were associated with at least one productive *TRA* (*TRB*, respectively) rearrangement. The filtered contig annotations, which contained high-level annotations of each high-confident cellular contig, were further filtered by removing the records with 'raw_consensus_id' as 'none'. Of all detected clonotypes, 81.22% contained one *TRA* and one *TRB* sequences, and 10.23% contained two *TRA* and one *TRB* sequences. Only 1.78% of clonotypes contained one *TRA* and two *TRB* sequences and only 1.47% of clonotypes had two *TRA* and two *TRB* sequences on average. In total, 91.23% of all CD3+ T cells could be assigned an $\alpha\beta$ TCR sequence. Within the CD4+ and CD8+ datasets, TCR sequences could be detected in 98.88% and 91.04% of cells, respectively. The CD3+ and CD8+ datasets contain additional cells lacking $\alpha\beta$ TCRs, such as CD4-CD8- and CD8+ $\gamma\delta$ T cells, respectively, which account for the lower % of cells.

Raw $\gamma\delta$ TCR sequencing data were processed using 10X Genomics Cell Ranger VDJ (v3.0.0) aligned to the GRCh38 V(D)J reference genome (v3.1.0, from 10X Genomics). Prevalence of *TRDV* gene usage was determined among bona fide $\gamma\delta$ T cells containing both productive *TRG* and *TRD* rearrangements, as many $\alpha\beta$ T cells also productively rearrange the *TRG* loci as previously reported and evident in our data (Sherwood et al., 2011).

Cluster relationships of clonally expanded T cells

On average, we could detect 1,967 unique $\alpha\beta$ TCR clonotypes in each patient (ranging from 1,247 to 2,678 among all patient samples). For the total 43,262 unique clonotypes detected in all patient samples, clonotype size ranged from 1 to 446 cells and 12.29% of clonotypes were expanded. An expanded clonotype was defined as a clonotype that could be detected in at least two cells. In the CD4+ or CD8+ T cell subsets, we further separated TCR clonotypes into the three corresponding patient groups (+CPI colitis, +CPI no colitis, control). A shared clonotype was defined as a TCR that could be detected in at least one cell in two different clusters. In the CD4+ T cell subset, we identified 148, 93 and 62 shared clonotypes between any two clusters in control, +CPI no-colitis and +CPI colitis groups, respectively. In the CD8+ T cell subset, we identified 245, 148 and 867 shared clonotypes in control, +CPI no colitis and +CPI colitis groups, respectively. In order to statistically test the cluster relationships in terms of clonal expansion for all shared clonotypes, we counted the number of shared clonotypes among different clusters, and then applied the one-sided Fisher's exact test (followed with Benjamini-Hochberg multiple test correction) on 2x2 cluster-by-cluster contingency tables to evaluate the significance of clone sharing between clusters. Finally, Cytoscape was used to visualize clonotype sharing between different clusters, with the nodes representing the clusters and the lines reflecting the number of shared clonotypes as well as the statistical significance of clonotype sharing between two clusters (Shannon et al., 2003).

Calculation of gene set activity score

In order to evaluate whether a hallmark gene set or another related gene set was enriched among the top ranking expressed genes in each cell, we calculated a gene set activity score for each gene set by applying an area under the curve method named `AUCcell` (v1.7.2, R package) (Aibar et al., 2017). For query gene set, we built the area under the recovery (AUC) curve based on the ranking of the top 1,500 genes in each single cell; the x axis is the ranking of expressed genes from high to low based on their expression values, and the y axis is the number of genes recovered from the query gene set. The gene set activity score is measured as the proportion of expressed genes in the query gene set and their relative expression levels compared to the other genes in each cell. NLRP3

inflammasome related gene sets used in the analyses included “GO_POSITIVE_REGULATION_OF_NLRP3_INFLAMMASOME_COMPLEX_ASSEMBLY” (*TLR6*, *GBP5*, *USP50*, *DHX33*, *TLR4*, *ATAT1*, and *CD36*) from MSigDB GO gene sets (Liberzon et al., 2015) and a custom gene set “NLRP3 inflammasome core pathway” (*IL1B*, *NLRP3*, *PYCARD*, *CASP1*, *GSDMD* and *IL18*).

Evaluation of co-activation potentiality

Guilt-by-association analysis was applied to evaluate the co-activation probability of *IL1B* gene expression and NLRP3 inflammasome core pathway activity in single cells (Walker et al., 1999). Specifically, for all myeloid cells from each patient group, the expression values of *IL1B* gene and activity scores of NLRP3 inflammasome core pathway were first z-score-normalized across all cells, respectively. Then a binary vector was constructed for each of the normalized vectors with the following strategy: the binary value was set to 1 if the corresponding z-scored value > 0, otherwise the binary value was 0. Finally, the P value for observing co-activation of *IL1B* gene expression and NLRP3 inflammasome core pathway activity were determined by one-sided Fisher’s exact test based on a 2 × 2 contingency table generated from the binary vectors.

Ligand-receptor expression and cell interactions

We examined the interaction of different cell types based on the expression level of ligand-receptor pairs in the CD45+ dataset. The specific ligand-receptor pairs were analyzed separately for chemokines (*CCL17-CCR4*, *CCL22-CCR4*, *CCL3-CCR5*, *CCL4-CCR5*, *CCL5-CCR5*, *CCL20-CCR6*, *CCL19-CCR7*, *CCL21-CCR7*, *CXCL9-CXCR3*, *CXCL10-CXCR3*, *CXCL11-CXCR3*, *CXCL12-CXCR4*, *CXCL13-CXCR5*, *CXCL16-CXCR6*, *XCL1-XCR1*, *XCL2-XCR1*) and cytokines (*AREG-EGFR*, *CSF2-CSF2RA*, *IFNG-IFNGR1*, *IL10-IL10RA/B*, *IL12-IL12RA*, *IL12A-IL12RB1*, *IL15-IL15RA*, *IL17A-IL17RA*, *IL17F-IL17RA*, *IL18-IL18R*, *IL1B-IL1R1*, *IL2-IL2RA/B/G*, *IL21-IL21R*, *IL22-IL22RA1*, *IL23-IL23R*, *IL6-IL6R*, *IL7-IL7R*, *LTB-LTBR*, *TNF-TNFRSF1A*, *TGFB1-TGFBR1/2*). To test whether the sender cell cluster is significantly communicated with the receiver cell cluster from the expression level of their ligand and receptor genes, we first averaged the normalized expression value of each ligand gene in cluster *i* as $E_{L,i}$ and receptor gene in cluster *j* as $E_{R,j}$, and then inferred that cluster *i* could interact with cluster *j* if the $E_{L,i} > 1$ and $E_{R,j} > 1$. The circlize (v0.4.8, R package) was used to visualize the interaction of different clusters (Gu et al., 2014). As a more quantitative metric, we defined the ligand-receptor score as $S_{L,R} = E_{L,i} * E_{R,j}$ with $E_{L,i} > 1$ and $E_{R,j} > 1$ and applied a permutation test to evaluate whether the inferred cluster interaction was statistically significant (Martin et al., 2019). Briefly, we first shuffled the cluster identity of each cell randomly for 10,000 times with the size of each cluster consistent with the truth, and then calculated the ligand-receptor scores again based on permuted data. Finally, a permutation P value was evaluated as the number of times that $S_{random} > S_{true}$ divided by 10,000.

Supplemental Figures




Figure S1. Overview of CD45⁺ Immune Cell Populations in Colitis and Control Patients, Related to Figure 1

(A) Gating strategy used for flow-sorting of CD45⁺ mononuclear cells (MNC) and CD3⁺ T cells. CD3⁺ sort gate encompassed CD3-low cells that can represent recently activated T cells with downregulated TCR-CD3 complex. Granulocytes are present in colitis lesions but CD66b⁺ neutrophils were removed by FACS because their high RNase content interferes with the 10X Genomics scRNA-seq platform (Geukes Foppen et al., 2018; Martin et al., 2019; Smillie et al., 2019).


(B) Quality metrics for CD45⁺ MNC dataset. Average of patients within each group with error bars (standard error of the mean).

(C) Heatmap showing differentially expressed genes across clusters in the CD45⁺ scRNA-seq dataset (Figure 1C). The top 10 genes differentially expressed in each cluster determined by ranked averaged log (fold change) are shown. Few non-immunoglobulin variable genes were significant for plasma B cells.

(D) CD45⁺ cells clustered and colored according to cell identify as in Figure 1C and split by patient group. Top, aggregated data from patients for each indicated group. Bottom, data from three +CPI colitis patients who received different CPI treatment regimens, including monotherapy with ipilimumab (ipi, patient C2).

(E) Gating strategy used for flow cytometry analysis of CD3⁺ T cells in Figure 1H and as a starting gate for subsequent T cell analyses.

(F) CD3⁺ T cell count per mg of biopsy tissue (n = 7-9 subjects per group, see Table S5 for details on analyzed cases) averaged across colon regions. Statistical analysis by Kruskal Wallis test corrected for multiple comparisons (*p < 0.05; error bars, SD). Accuracy of tissue weight measurements was likely affected by incomplete removal of collection media; complete removal of media and tissue dehydration could compromise scRNA-seq data quality.



(legend on next page)

Figure S2. Colitis-Related T Cell Clusters in the CD3⁺ scRNA-Seq Dataset, Related to Figure 2

(A) Identification of major cell clusters of CD3⁺ T cells from colon biopsies, shown as UMAP of cells grouped by the Louvain clustering algorithm. CD45⁺ cells were analyzed from 16 subjects but CD3⁺ cells from 22 subjects because preliminary data analysis identified a major change in the T cell compartment in colitis compared to control cases.

(B) Feature plots showing normalized expression of *CD4* and *CD8A*.

(C) Expression of most highly cluster-associated genes (2 per cluster), representing the highest-scoring differentially expressed genes calculated from cell-type specificity score (see [STAR Methods](#)). y axis represents the normalized gene expression value. See [Table S6](#) for all marker genes.

(D) Quantification of cell cluster frequency between patient groups. For each cluster, the average fraction of cells from each patient group is shown, after normalization for total input cell numbers per patient (see [STAR Methods](#)). Average and SEM shown. Statistical analysis compares healthy control and +CPI-colitis patients as a two-sided Wilcoxon test (*p < 0.05, **p < 0.01, ***p < 0.001; error bars, SD).

(E) Distribution of CD3⁺ T cells across clusters in the three patient groups.

(F) Cell cluster frequency shown as a fraction of total cells for each patient, CT, control; NC, no colitis; C, colitis.





(G) Representation of cells from individual patients within each cluster based on normalized cell numbers per patient (see [STAR Methods](#)), demonstrating that all clusters contained cells from multiple patients and thus were not related to patient-specific batch effects.

(H) Effect of enzymatic digestion on CD8 α surface expression as shown by flow cytometry analysis of PBMCs (sample unrelated to study). PBMCs were incubated with and without tissue digestion enzyme mixture as performed for dissociation of colon biopsies.

(I and J) Gating strategy for enumeration of CD8⁺ $\alpha\beta$ T cells, and statistical analysis for all patients shown by one-way ANOVA test.

(K) Quantification of $\gamma\delta$ T cell frequency averaged across colon regions (% of CD3⁺ cells pre-gated as in [Figure S1E](#)) by flow cytometry, including gating of representative sample. Statistical analysis for all patients (n = 7-10 subjects per group, see [Table S5](#) for details on analyzed cases) shown by Brown-Forsyth and Welch ANOVA test (*p < 0.05).

(L) Quantification of MAIT cell frequencies averaged across colon regions (% of $\gamma\delta$ TCR⁺ CD4⁻ cells pre-gated as in [Figure S2I](#)) by flow cytometry. Statistical analysis for all patients (n = 7-10 subjects per group, see [Table S5](#) for details on analyzed cases) shown by Brown-Forsyth and Welch ANOVA test (*p < 0.05).



(legend on next page)

Figure S3. Characterization of Colitis-Associated Changes in CD8 T Cell Populations, Related to Figure 2


(A) Representation of cells from individual patients within each CD8 T cell cluster, based on normalized cell numbers per patient (see [STAR Methods](#)), demonstrating that all clusters contained cells from multiple patients and therefore were not related to patient-specific batch effects.

(B) Heatmap showing differentially expressed genes across CD8 T cell sub-clusters. The top 10 cluster-associated genes are shown, determined and ranked by averaged log (fold change) compared to all other clusters.

(C) Top differentially expressed genes for colitis-associated CD8 T cell clusters (5-8) compared to all other clusters (1-4). Normalized gene expression shown as feature plots containing cells combined from all patients.

(D) Normalized *IFNG* expression shown as feature plots for each patient cohort (combined cells from all patients within each group).

(E) Analysis of T cell populations from a +CPI colitis patient who received α -CTLA-4 monotherapy (α -Ki-67 and α -CD103 antibodies were not included in this earlier version of the antibody panel).



(legend on next page)

Figure S4. Characterization of Colitis-Associated Changes in CD4 T Cell Populations, Related to Figure 3

(A) Heatmap showing differentially expressed genes across CD4 T cell sub-clusters. The top 10 cluster-associated genes are shown, determined and ranked by averaged log (fold change).

(B) Cell cluster frequency shown as a fraction of total cells for each patient, CT, control; NC, no colitis; C, colitis.

(C) Top differentially expressed genes in colitis-associated clusters (9-10) compared to all other clusters (1-8). Normalized gene expression shown as feature plots displaying cells combined from all patients.

(D) Normalized *IFNG* expression shown as feature plots for each patient cohort (combined cells from all patients within each group).


(E) Analysis of Tregs in +CPI colitis patient C2 who received α -CTLA-4 monotherapy. Quantification of FoxP3+ T cells (left) and Treg frequency (% CD4+ T cells) in patient C2 (red) compared to other +CPI colitis patients averaged across colon regions (right).

(F) Quantification of Treg cell numbers per mg of biopsy tissue (n = 7-9 subjects per group, see Table S5 for details on analyzed cases) averaged across colon regions. Statistical analysis by Kruskal Wallis test corrected for multiple comparisons (**p < 0.01; error bars, SD). Accuracy of tissue weight measurements was likely affected by incomplete removal of collection media.

(G) *FOXP3* normalized gene expression shown for single cells in Treg sub-clusters from Figure 3L.

(H) Quantification of Treg cell cluster frequency between patient groups. For each cluster, the average fraction of cells from each patient group is shown, after normalization for total input cell numbers per patient (see STAR Methods). Average and SEM shown for the patient groups. Statistical analysis compares control and +CPI colitis patients as a two-sided Wilcoxon test (*p < 0.05, **p < 0.01, ***p < 0.001).

(I) Representation of Treg cells from individual patients within each Treg sub-cluster based on normalized cell numbers per patient (see STAR Methods), demonstrating that all clusters contained cells from multiple patients.



(D) Sharing of expanded TCR clonotypes across CD4 T cell clusters. For each patient and cluster, the number of expanded TCR clonotypes from the CD4 T cell dataset was calculated and summed together for the indicated patient groups. Expanded clonotypes shared with a colitis-associated cluster (9-10) are colored red, those shared with other clusters (1-8) are colored blue.

(E) Sharing of expanded TCR clonotypes across all possible combinations of CD4 T cell clusters. Data were aggregated for each of the indicated patient groups. Numbers indicate the number of shared expanded TCR clonotypes for each cluster pair. Bold boxes indicate statistically significant sharing of expanded clonotypes between clusters (adjusted $p < 0.05$, one-sided Fisher's exact test followed with Benjamini-Hochberg correction).

(F) Method for sequencing of $\gamma\delta$ TCR chains from 5' scRNA-seq libraries. TRGC and TRDC primer binding sites of nested primers are shown visualized with SnapGene software (GSL Biotech).

(G) Quantification of top $\gamma\delta$ TCR clonotypes. For each patient, the percentage of cells expressing the top $\gamma\delta$ TCR clonotype out of total $\gamma\delta$ TCR+ cells is shown; p value, Kruskal-Wallis test; error bars, SD.

(H) Quantification of $\gamma\delta$ TCR V gene (TRDV) usage. For each patient, the % of TCRs using each TRDV gene was calculated. Statistical analysis by two-way ANOVA test with Tukey's multiple comparisons test.




Figure S6. Colitis-Associated Changes in T Cell Gene Expression Programs, Related to Figure 5

(A) Representative plots showing CTLA-4 protein expression on CD8 T cells by flow cytometry. Cells were pre-gated based on a CD4⁻αβTCR⁺ non-MAIT (Va7.2⁺ CD161⁺) phenotype among live CD45⁺ CD3⁺ cells.

(B) Quantification of CTLA-4+ CD8+ T cells (left) and CTLA-4+ granzyme B+ CD8+ T cells for the indicated patient groups (n = 6-10 subjects per group, see Table S5 for details on analyzed cases) averaged across colon regions. Statistical analysis by Kruskal-Wallis test (*p < 0.05, **p < 0.01; error bars, SD).

(C) Quantification of CTLA-4⁺ Foxp3⁻ effector CD4⁺ T cells (n = 6-10 subjects per group, see Table S5 for details on analyzed cases). Gating as in Figure 3I.

(D) Normalized expression of *CTLA4* and *PDCD1* genes among CD8 T cells, split by patient cohorts (combined patients within each group).

(E) Normalized expression of *CTLA4* and *PDCD1* genes among CD4 T cells, split by patient cohorts (combined patients within each group).

(F) Analysis of Hallmark gene sets enriched in colitis-associated clusters, shown for both CD8 and CD4 datasets. For the CD8 analysis, clusters 5-8 were compared to clusters 1-4; for the CD4 analysis, clusters 9-10 were compared to clusters 1-8. NES = normalized enrichment score.




Figure S7. Expression of Chemokine, Cytokine, and Integrin Genes in Relation to Colitis, Related to Figure 7

(A) Averaged log (fold change) of indicated chemokine receptor/ligands, compared between +CPI colitis and healthy control subjects from CD45+ dataset
(B) Normalized gene expression for molecules involved in T cell migration and tissue residency, shown for CD4 and CD8 T cell datasets.

(legend continued on next page)

(C) Averaged log (fold change) for indicated cytokine receptor and ligand genes, compared between +CPI colitis and healthy control groups. Expression is shown for either T cell clusters (#11-16) or myeloid cluster (#5) from CD45+ dataset.

(D) Normalized expression of indicated cytokines genes in myeloid cells (Figure 6D) split by patient cohorts (combined patients within each group).

(E) Activity score for positive regulation of NLRP3 inflammasome expression shown for myeloid sub-clusters (Figure 6E). Two-sided Wilcoxon-test p value for increased activity score expression in cluster 1 is shown.

(F) Activity score for NLRP3 inflammasome core pathway shown for myeloid sub-clusters. Two-sided Wilcoxon-test p value for increased activity score expression in clusters 1 and 2.

(G) Left, blended feature plots of *IL1B* gene expression and NLRP3 inflammasome core pathway activity score shown for single cells displayed as a UMAP projection. Right, statistical significance for co-activation of IL1B and NLRP3 inflammasome core pathway activity score calculated using Guilt-By-Association, shown for all myeloid cells in the indicated patient groups.